BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer. 2000;83:1301-1308. [PMID: 11044354 DOI: 10.1054/bjoc.2000.1407] [Cited by in Crossref: 412] [Cited by in F6Publishing: 353] [Article Influence: 19.6] [Reference Citation Analysis]
Number Citing Articles
1 Ameziane N, van den Ouweland AMW, Adank MA, Vijzelaar RNCP, Errami A, Dorsman JC, Joenje H, Meijers-heijboer H, Waisfisz Q. Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer. Breast Cancer Res Treat 2009;118:651-3. [DOI: 10.1007/s10549-009-0428-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bergfeldt K, Rydh B, Granath F, Grönberg H, Thalib L, Adami H, Hall P. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. The Lancet 2002;360:891-4. [DOI: 10.1016/s0140-6736(02)11023-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
3 Lacaze P, Bakshi A, Riaz M, Orchard SG, Tiller J, Neumann JT, Carr PR, Joshi AD, Cao Y, Warner ET, Manning A, Nguyen-Dumont T, Southey MC, Milne RL, Ford L, Sebra R, Schadt E, Gately L, Gibbs P, Thompson BA, Macrae FA, James P, Winship I, McLean C, Zalcberg JR, Woods RL, Chan AT, Murray AM, McNeil JJ. Genomic Risk Prediction for Breast Cancer in Older Women. Cancers (Basel) 2021;13:3533. [PMID: 34298747 DOI: 10.3390/cancers13143533] [Reference Citation Analysis]
4 McClain MR, Nathanson KL, Palomaki GE, Haddow JE. An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. Genet Med 2005;7:34-9. [PMID: 15654226 DOI: 10.1097/01.gim.0000151156.14983.08] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
5 Vikrant, Sawant UU, Varma AK. Role of MERIT40 in stabilization of BRCA1 complex: a protein-protein interaction study. Biochem Biophys Res Commun 2014;446:1139-44. [PMID: 24667604 DOI: 10.1016/j.bbrc.2014.03.073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
6 Marroni F, Aretini P, D'andrea E, Caligo MA, Cortesi L, Viel A, Ricevuto E, Montagna M, Cipollini G, Federico M, Santarosa M, Marchetti P, Bailey-wilson JE, Bevilacqua G, Parmigiani G, Presciuttini S. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet 2004;12:899-906. [DOI: 10.1038/sj.ejhg.5201256] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
7 Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat 2011;126:771-8. [PMID: 20927582 DOI: 10.1007/s10549-010-1195-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
8 D'Andrea E, Marzuillo C, De Vito C, Di Marco M, Pitini E, Vacchio MR, Villari P. Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations. Genet Med 2016;18:1171-80. [PMID: 27906166 DOI: 10.1038/gim.2016.29] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
9 Klaren HM, van't Veer LJ, van Leeuwen FE, Rookus MA. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst 2003;95:941-7. [PMID: 12837830 DOI: 10.1093/jnci/95.13.941] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
10 Melzer D, Frayling TM, Murray A, Hurst AJ, Harries LW, Song H, Khaw K, Luben R, Surtees PG, Bandinelli SS, Corsi AM, Ferrucci L, Guralnik JM, Wallace RB, Hattersley AT, Pharoah PD. A common variant of the p16(INK4a) genetic region is associated with physical function in older people. Mech Ageing Dev 2007;128:370-7. [PMID: 17459456 DOI: 10.1016/j.mad.2007.03.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
11 Meyer LA, Anderson ME, Lacour RA, Suri A, Daniels MS, Urbauer DL, Nogueras-Gonzalez GM, Schmeler KM, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol 2010;115:945-52. [PMID: 20410767 DOI: 10.1097/AOG.0b013e3181da08d7] [Cited by in Crossref: 82] [Cited by in F6Publishing: 41] [Article Influence: 7.5] [Reference Citation Analysis]
12 Honrado E, Osorio A, Palacios J, Milne RL, Sánchez L, Díez O, Cazorla A, Syrjakoski K, Huntsman D, Heikkilä P, Lerma E, Kallioniemi A, Rivas C, Foulkes WD, Nevanlinna H, Benítez J. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol 2005;23:7503-11. [PMID: 16234517 DOI: 10.1200/JCO.2005.01.3698] [Cited by in Crossref: 50] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
13 Catucci I, Milgrom R, Kushnir A, Laitman Y, Paluch-shimon S, Volorio S, Ficarazzi F, Bernard L, Radice P, Friedman E, Peterlongo P. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. Familial Cancer 2012;11:483-91. [DOI: 10.1007/s10689-012-9540-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
14 Knuttel FM, Huijsse SEM, Feenstra TL, Moonen CTW, van den Bosch MAAJ, Buskens E, Greuter MJW, de Bock GH. Early health technology assessment of magnetic resonance-guided high intensity focused ultrasound ablation for the treatment of early-stage breast cancer. J Ther Ultrasound 2017;5:23. [PMID: 28781881 DOI: 10.1186/s40349-017-0101-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, Pharoah PD, Ponder BA, Meuth M, Bhattacharyya NP, Cox A. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 2004;96:1866-9. [PMID: 15601643 DOI: 10.1093/jnci/dji001] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 5.9] [Reference Citation Analysis]
16 Vuković P, Peccatori FA, Massarotti C, Miralles MS, Beketić-Orešković L, Lambertini M. Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants. Crit Rev Oncol Hematol 2021;157:103201. [PMID: 33333149 DOI: 10.1016/j.critrevonc.2020.103201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
17 Abul-Husn NS, Soper ER, Odgis JA, Cullina S, Bobo D, Moscati A, Rodriguez JE, Loos RJF, Cho JH, Belbin GM, Suckiel SA, Kenny EE; CBIPM Genomics Team., Regeneron Genetics Center. Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank. Genome Med 2019;12:2. [PMID: 31892343 DOI: 10.1186/s13073-019-0691-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
18 Eerola H, Aittomäki K, Asko-seljavaara S, Nevanlinna H, von Smitten K. Hereditary Breast Cancer and Handling of Patients at Risk. Scand J Surg 2002;91:280-7. [DOI: 10.1177/145749690209100312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ticha I, Kleibl Z, Stribrna J, Kotlas J, Zimovjanova M, Mateju M, Zikan M, Pohlreich P. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene. Breast Cancer Res Treat 2010;124:337-47. [PMID: 20135348 DOI: 10.1007/s10549-010-0745-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
20 Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, Ponder BJ, Easton DF. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002;86:76-83. [PMID: 11857015 DOI: 10.1038/sj.bjc.6600008] [Cited by in Crossref: 301] [Cited by in F6Publishing: 239] [Article Influence: 15.8] [Reference Citation Analysis]
21 Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast Cancer Res Treat. 2015;149:223-227. [PMID: 25476495 DOI: 10.1007/s10549-014-3218-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
22 Jervis S, Song H, Lee A, Dicks E, Harrington P, Baynes C, Manchanda R, Easton DF, Jacobs I, Pharoah PP, Antoniou AC. A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. J Med Genet 2015;52:465-75. [PMID: 26025000 DOI: 10.1136/jmedgenet-2015-103077] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
23 Benusiglio PR, Lesueur F, Luccarini C, Conroy DM, Shah M, Easton DF, Day NE, Dunning AM, Pharoah PD, Ponder BA. Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 2005;7:R204-9. [PMID: 15743501 DOI: 10.1186/bcr982] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
24 Bradbury AR, Olopade OI. Genetic susceptibility to breast cancer. Rev Endocr Metab Disord 2007;8:255-67. [DOI: 10.1007/s11154-007-9038-0] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
25 McClain MR, Palomaki GE, Nathanson KL, Haddow JE. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 2005;7:28-33. [PMID: 15654225 DOI: 10.1097/01.gim.0000151155.36470.ff] [Cited by in Crossref: 57] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
26 Park B, Dowty JG, Ahn C, Win AK, Kim S, Lee MH, Lee JW, Kang E, Hopper JL, Park SK. Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2. Breast Cancer Res Treat 2015;152:659-65. [DOI: 10.1007/s10549-015-3495-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
27 Tulsyan S, Agarwal G, Lal P, Agrawal S, Mittal RD, Mittal B. CD44 gene polymorphisms in breast cancer risk and prognosis: a study in North Indian population. PLoS One 2013;8:e71073. [PMID: 23940692 DOI: 10.1371/journal.pone.0071073] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
28 Snyder CL, Lynch JF, Lynch HT. Genetic counseling and the advanced practice oncology nursing role in a hereditary cancer prevention clinic: hereditary breast cancer focus (part I). Breast J 2009;15 Suppl 1:S2-10. [PMID: 19775325 DOI: 10.1111/j.1524-4741.2009.00802.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
29 Long KC, Kauff ND. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. Curr Opin Oncol 2011;23:526-30. [PMID: 21734577 DOI: 10.1097/CCO.0b013e3283499da9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
30 Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 2013;5 Suppl 1:S2-8. [PMID: 23819024 DOI: 10.3978/j.issn.2072-1439.2013.05.24] [Cited by in F6Publishing: 83] [Reference Citation Analysis]
31 Manickam K, Buchanan AH, Schwartz MLB, Hallquist MLG, Williams JL, Rahm AK, Rocha H, Savatt JM, Evans AE, Butry LM, Lazzeri AL, Lindbuchler DM, Flansburg CN, Leeming R, Vogel VG, Lebo MS, Mason-Suares HM, Hoskinson DC, Abul-Husn NS, Dewey FE, Overton JD, Reid JG, Baras A, Willard HF, McCormick CZ, Krishnamurthy SB, Hartzel DN, Kost KA, Lavage DR, Sturm AC, Frisbie LR, Person TN, Metpally RP, Giovanni MA, Lowry LE, Leader JB, Ritchie MD, Carey DJ, Justice AE, Kirchner HL, Faucett WA, Williams MS, Ledbetter DH, Murray MF. Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants. JAMA Netw Open 2018;1:e182140. [PMID: 30646163 DOI: 10.1001/jamanetworkopen.2018.2140] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 28.0] [Reference Citation Analysis]
32 Winship I, Southey MC. Gene panel testing for hereditary breast cancer. Med J Aust 2016;204:188-90. [PMID: 26985847 DOI: 10.5694/mja15.01335] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
33 Woodward ER, van Veen EM, Evans DG. From BRCA1 to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related Genes. Breast Care (Basel) 2021;16:202-13. [PMID: 34248461 DOI: 10.1159/000515319] [Reference Citation Analysis]
34 Haffty BG, Choi DH, Goyal S, Silber A, Ranieri K, Matloff E, Lee MH, Nissenblatt M, Toppmeyer D, Moran MS. Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. Ann Oncol 2009;20:1653-9. [PMID: 19491284 DOI: 10.1093/annonc/mdp051] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
35 de Mayo T, Ziegler A, Morales S, Jara L. Identification of a Rare Germline Heterozygous Deletion Involving the Polycistronic miR-17-92 Cluster in Two First-Degree Relatives from a BRCA 1/2 Negative Chilean Family with Familial Breast Cancer: Possible Functional Implications. Int J Mol Sci 2018;19:E321. [PMID: 29361751 DOI: 10.3390/ijms19010321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
36 Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 2001;93:1215-23. [PMID: 11504767 DOI: 10.1093/jnci/93.16.1215] [Cited by in Crossref: 158] [Cited by in F6Publishing: 145] [Article Influence: 7.9] [Reference Citation Analysis]
37 Pace LE, Tung N, Lee YS, Hamilton JG, Gabriel C, Revette A, Raja S, Jenkins C, Braswell A, Morgan K, Levin J, Block J, Domchek SM, Nathanson K, Symecko H, Spielman K, Karlan B, Kamara D, Lester J, Offit K, Garber JE, Keating NL. Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study. J Gen Intern Med 2021. [PMID: 34173196 DOI: 10.1007/s11606-021-06970-8] [Reference Citation Analysis]
38 Orenstein L, Chetrit A, Dankner R. Healthy Lifestyle Pattern is Protective Against 30-Yr Cancer Incidence in Men and Women: A Cohort Study. Nutr Cancer 2016;68:410-9. [PMID: 27007270 DOI: 10.1080/01635581.2016.1153673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
39 De Nicolo A, Tancredi M, Lombardi G, Flemma CC, Barbuti S, Di Cristofano C, Sobhian B, Bevilacqua G, Drapkin R, Caligo MA. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clin Cancer Res. 2008;14:4672-4680. [PMID: 18628483 DOI: 10.1158/1078-0432.CCR-08-0087] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
40 Offit K. BRCA mutation frequency and penetrance: new data, old debate. J Natl Cancer Inst 2006;98:1675-7. [PMID: 17148764 DOI: 10.1093/jnci/djj500] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
41 Cloud AJ, Thai A, Liao Y, Terry MB. The impact of cancer prevention guideline adherence on overall mortality in a high-risk cohort of women from the New York site of the Breast Cancer Family Registry. Breast Cancer Res Treat 2015;149:537-46. [PMID: 25604794 DOI: 10.1007/s10549-014-3234-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
42 Reed AM, Fishel ML, Kelley MR. Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation. Future Oncol 2009;5:713-26. [PMID: 19519210 DOI: 10.2217/fon.09.31] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
43 Rainville IR, Rana HQ. Next-generation sequencing for inherited breast cancer risk: counseling through the complexity. Curr Oncol Rep. 2014;16:371. [PMID: 24488544 DOI: 10.1007/s11912-013-0371-z] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
44 Haitian Z, Yunfei L, Jian Z, Jian L, Qinghua L, Fuqiang W. Mutation screening of the BRCA1 gene in sporadic breast cancer in southern Chinese populations. The Breast 2008;17:563-7. [DOI: 10.1016/j.breast.2008.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
45 Ahmed M, Lalloo F, Evans DG. Update on genetic predisposition to breast cancer. Expert Review of Anticancer Therapy 2014;9:1103-13. [DOI: 10.1586/era.09.38] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
46 Brandt A, Lorenzo Bermejo J, Sundquist J, Hemminki K. Breast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start? Breast Cancer Res Treat 2010;121:133-41. [DOI: 10.1007/s10549-009-0486-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
47 Seong MW, Cho S, Noh DY, Han W, Kim SW, Park CM, Park HW, Kim SY, Kim JY, Park SS. Comprehensive mutational analysis of BRCA1/BRCA2 for Korean breast cancer patients: evidence of a founder mutation. Clin Genet 2009;76:152-60. [PMID: 19656164 DOI: 10.1111/j.1399-0004.2009.01202.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
48 Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM; SEARCH breast cancer study. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 2007;9:R27. [PMID: 17428325 DOI: 10.1186/bcr1669] [Cited by in Crossref: 78] [Cited by in F6Publishing: 64] [Article Influence: 5.6] [Reference Citation Analysis]
49 Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Lubinski J. The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2010;121:639-49. [PMID: 19876733 DOI: 10.1007/s10549-009-0595-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
50 Maxwell KN, Nathanson KL. Common breast cancer risk variants in the post-COGS era: a comprehensive review. Breast Cancer Res 2013;15:212. [PMID: 24359602 DOI: 10.1186/bcr3591] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
51 Vaidya AM, Chetlen AL, Schetter SE. Does a High-Risk Recommendation in Mammography Reports Increase Attendance at a Breast Cancer Risk Assessment Clinic? Journal of the American College of Radiology 2015;12:923-9. [DOI: 10.1016/j.jacr.2015.04.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
52 Saunders CL, Begg CB. Kin-cohort evaluation of relative risks of genetic variants. Genet Epidemiol 2003;24:220-9. [PMID: 12652526 DOI: 10.1002/gepi.10235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
53 Pruss D, Morris B, Hughes E, Eggington JM, Esterling L, Robinson BS, van Kan A, Fernandes PH, Roa BB, Gutin A. Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes. Breast Cancer Res Treat. 2014;147:119-132. [PMID: 25085752 DOI: 10.1007/s10549-014-3065-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
54 Smith-Uffen M, Bartley N, Davies G, Best M. Motivations and barriers to pursue cancer genomic testing: A systematic review. Patient Educ Couns 2021;104:1325-34. [PMID: 33390305 DOI: 10.1016/j.pec.2020.12.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Arason A, Gunnarsson H, Johannesdottir G, Jonasson K, Bendahl PO, Gillanders EM, Agnarsson BA, Jönsson G, Pylkäs K, Mustonen A, Heikkinen T, Aittomäki K, Blomqvist C, Melin B, Johannsson OT, Møller P, Winqvist R, Nevanlinna H, Borg A, Barkardottir RB. Genome-wide search for breast cancer linkage in large Icelandic non-BRCA1/2 families. Breast Cancer Res 2010;12:R50. [PMID: 20637093 DOI: 10.1186/bcr2608] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
56 Vargas AC, Reis-Filho JS, Lakhani SR. Phenotype-genotype correlation in familial breast cancer. J Mammary Gland Biol Neoplasia 2011;16:27-40. [PMID: 21400086 DOI: 10.1007/s10911-011-9204-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
57 Cai Y, Li J, Gao Y, Yang K, He J, Li N, Tian J. A systematic review of recommendations on screening strategies for breast cancer due to hereditary predisposition: Who, When, and How? Cancer Med 2021;10:3437-48. [PMID: 33932123 DOI: 10.1002/cam4.3898] [Reference Citation Analysis]
58 Wendt C, Margolin S. Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer. Acta Oncol 2019;58:135-46. [PMID: 30606073 DOI: 10.1080/0284186X.2018.1529428] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 14.5] [Reference Citation Analysis]
59 Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009;3:97-137. [PMID: 19383374 DOI: 10.1016/j.molonc.2009.02.004] [Cited by in Crossref: 121] [Cited by in F6Publishing: 91] [Article Influence: 10.1] [Reference Citation Analysis]
60 Hurry M, Eccleston A, Dyer M, Hoskins P. Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops. Int J Technol Assess Health Care 2020;36:104-12. [PMID: 32423520 DOI: 10.1017/S0266462319003519] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
61 De Vecchi G, Verderio P, Pizzamiglio S, Manoukian S, Bernard L, Pensotti V, Volorio S, Ravagnani F, Radice P, Peterlongo P. The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detection and Prevention 2008;32:140-3. [DOI: 10.1016/j.cdp.2008.06.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
62 Geredeli C, Yasar N, Sakin A. Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population. Int J Breast Cancer 2019;2019:9645147. [PMID: 30713775 DOI: 10.1155/2019/9645147] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
63 Gallagher S, Hughes E, Wagner S, Tshiaba P, Rosenthal E, Roa BB, Kurian AW, Domchek SM, Garber J, Lancaster J, Weitzel JN, Gutin A, Lanchbury JS, Robson M. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. JAMA Netw Open 2020;3:e208501. [PMID: 32609350 DOI: 10.1001/jamanetworkopen.2020.8501] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 33.0] [Reference Citation Analysis]
64 Malik FA, Ashraf S, Kayani MA, Jiang WG, Mir A, Ansar M, Baloch IA, Sadiq R. Contribution of BRCA1 germline mutation in patients with sporadic breast cancer. Int Semin Surg Oncol 2008;5:21. [PMID: 18759965 DOI: 10.1186/1477-7800-5-21] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
65 Witteveen A, Vliegen IM, Sonke GS, Klaase JM, IJzerman MJ, Siesling S. Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. Breast Cancer Res Treat 2015;152:627-36. [PMID: 26162567 DOI: 10.1007/s10549-015-3490-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
66 Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutson D, Kerber R, Amos CI, Strong LC, Berry DA, Euhus DM, Parmigiani G. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006;24:863-871. [PMID: 16484695 DOI: 10.1200/jco.2005.03.6772] [Cited by in Crossref: 230] [Cited by in F6Publishing: 103] [Article Influence: 15.3] [Reference Citation Analysis]
67 Solyom S, Aressy B, Pylkäs K, Patterson-Fortin J, Hartikainen JM, Kallioniemi A, Kauppila S, Nikkilä J, Kosma VM, Mannermaa A, Greenberg RA, Winqvist R. Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions. Sci Transl Med 2012;4:122ra23. [PMID: 22357538 DOI: 10.1126/scitranslmed.3003223] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
68 Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol. 2009;33:1878-1885. [PMID: 19898224 DOI: 10.1097/pas.0b013e3181bc6059] [Cited by in Crossref: 75] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
69 Abdel-Razeq H, Tamimi F, Abujamous L, Edaily S, Abunasser M, Bater R, Salama O. Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives. Cancer Manag Res 2021;13:4597-604. [PMID: 34135636 DOI: 10.2147/CMAR.S316470] [Reference Citation Analysis]
70 Purnomosari D, Paramita DK, Aryandono T, Pals G, van Diest PJ. A novel BRCA2 mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing. J Clin Pathol 2005;58:493-9. [PMID: 15858120 DOI: 10.1136/jcp.2004.020388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
71 Baurecht H, Irvine AD, Novak N, Illig T, Bühler B, Ring J, Wagenpfeil S, Weidinger S. Toward a major risk factor for atopic eczema: Meta-analysis of filaggrin polymorphism data. Journal of Allergy and Clinical Immunology 2007;120:1406-12. [DOI: 10.1016/j.jaci.2007.08.067] [Cited by in Crossref: 158] [Cited by in F6Publishing: 120] [Article Influence: 11.3] [Reference Citation Analysis]
72 Lewin AA, Kim SG, Babb JS, Melsaether AN, McKellop J, Moccaldi M, Klautau Leite AP, Moy L. Assessment of Background Parenchymal Enhancement and Lesion Kinetics in Breast MRI of BRCA 1/2 Mutation Carriers Compared to Matched Controls Using Quantitative Kinetic Analysis. Acad Radiol 2016;23:358-67. [PMID: 26774741 DOI: 10.1016/j.acra.2015.11.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
73 Lyngholm CD, Laurberg T, Alsner J, Damsgaard TE, Overgaard J, Christiansen PM. Failure pattern and survival after breast conserving therapy. Long-term results of the Danish Breast Cancer Group (DBCG) 89 TM cohort. Acta Oncologica 2016;55:983-92. [DOI: 10.3109/0284186x.2016.1156741] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
74 Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA, Easton DF. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 2005;29:1-11. [PMID: 15880399 DOI: 10.1002/gepi.20074] [Cited by in Crossref: 115] [Cited by in F6Publishing: 103] [Article Influence: 7.2] [Reference Citation Analysis]
75 Connor AA, Gallinger S. Hereditary Pancreatic Cancer Syndromes. Surg Oncol Clin N Am. 2015;24:733-764. [PMID: 26363539 DOI: 10.1016/j.soc.2015.06.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
76 Bahassi EM, Ovesen JL, Riesenberg AL, Bernstein WZ, Hasty PE, Stambrook PJ. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 2008;27:3977-85. [PMID: 18317453 DOI: 10.1038/onc.2008.17] [Cited by in Crossref: 107] [Cited by in F6Publishing: 93] [Article Influence: 8.2] [Reference Citation Analysis]
77 Jara L, Morales S, de Mayo T, Gonzalez-Hormazabal P, Carrasco V, Godoy R. Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations. Biol Res 2017;50:35. [PMID: 28985766 DOI: 10.1186/s40659-017-0139-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
78 Fachal L, Blanco A, Santamariña M, Carracedo A, Vega A. Large genomic rearrangements of BRCA1 and BRCA2 among patients referred for genetic analysis in Galicia (NW Spain): delimitation and mechanism of three novel BRCA1 rearrangements. PLoS One 2014;9:e93306. [PMID: 24686251 DOI: 10.1371/journal.pone.0093306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
79 Hamann U, Liu X, Bungardt N, Ulmer HU, Bastert G, Sinn H. Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany. Eur J Hum Genet 2003;11:464-7. [DOI: 10.1038/sj.ejhg.5200988] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
80 Vos JR, Hsu L, Brohet RM, Mourits MJ, de Vries J, Malone KE, Oosterwijk JC, de Bock GH. Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers. J Clin Oncol 2015;33:2553-62. [PMID: 26150446 DOI: 10.1200/JCO.2014.59.0463] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
81 Chand M, Moore PJ, Clarke AD, Nash GF, Hickisk T. A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer. World J Surg Oncol 2007;5:102. [PMID: 17850658 DOI: 10.1186/1477-7819-5-102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
82 Sigurdson AJ, Hauptmann M, Chatterjee N, Alexander BH, Doody MM, Rutter JL, Struewing JP. Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer 2004;4:9. [PMID: 15113441 DOI: 10.1186/1471-2407-4-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 3.4] [Reference Citation Analysis]
83 Rubinstein WS, Latimer JJ, Sumkin JH, Huerbin M, Grant SG, Vogel VG. Prospective screening study of 0.5 Tesla dedicated magnetic resonance imaging for the detection of breast cancer in young, high-risk women. BMC Womens Health 2006;6:10. [PMID: 16800895 DOI: 10.1186/1472-6874-6-10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
84 Col NF. The Use of Gene Tests to Detect Hereditary Predisposition to Chronic Disease: Is Cost-Effectiveness Analysis Relevant? Med Decis Making 2003;23:441-8. [DOI: 10.1177/0272989x03254456] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
85 Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Mæhle L, Undlien DE, Norum J, Schlichting E. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer 2017;17:438. [PMID: 28637432 DOI: 10.1186/s12885-017-3422-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
86 Ping Z, Xia Y, Shen T, Parekh V, Siegal GP, Eltoum IE, He J, Chen D, Deng M, Xi R, Shen D. A microscopic landscape of the invasive breast cancer genome. Sci Rep 2016;6:27545. [PMID: 27283966 DOI: 10.1038/srep27545] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
87 Balabanski L, Antov G, Dimova I, Ivanov S, Nacheva M, Gavrilov I, Nesheva D, Rukova B, Hadjidekova S, Malinov M, Toncheva D. Next-generation sequencing of BRCA1 and BRCA2 in breast cancer patients and control subjects. Mol Clin Oncol 2014;2:435-9. [PMID: 24772314 DOI: 10.3892/mco.2014.251] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
88 Bellcross CA, Leadbetter S, Alford SH, Peipins LA. Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral. Cancer Epidemiol Biomarkers Prev 2013;22:728-35. [PMID: 23371291 DOI: 10.1158/1055-9965.EPI-12-1280] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
89 Gal I, Kimmel G, Gershoni-Baruch R, Papa MZ, Dagan E, Shamir R, Friedman E. A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women. Eur J Cancer 2006;42:1129-34. [PMID: 16624550 DOI: 10.1016/j.ejca.2005.09.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
90 Ponder BA. Cancer genetics. Nature. 2001;411:336-341. [PMID: 11357140 DOI: 10.1038/35077207] [Cited by in Crossref: 361] [Cited by in F6Publishing: 277] [Article Influence: 18.1] [Reference Citation Analysis]
91 Loizidou M, Marcou Y, Anastasiadou V, Newbold R, Hadjisavvas A, Kyriacou K. Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus. Clin Genet 2007;71:165-70. [PMID: 17250666 DOI: 10.1111/j.1399-0004.2007.00747.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
92 Eachkoti R, Hussain I, Afroze D, Aejazaziz S, Jan M, Shah ZA, Das BC, Siddiqi MA. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. Cancer Lett 2007;248:308-20. [PMID: 16996204 DOI: 10.1016/j.canlet.2006.08.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
93 Chen L, Fu F, Huang M, Lv J, Zhang W, Wang C. The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer. Breast Cancer Res Treat 2020;180:759-66. [PMID: 32072338 DOI: 10.1007/s10549-020-05573-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
94 Meisel C, Sadowski CE, Kohlstedt D, Keller K, Stäritz F, Grübling N, Becker K, Mackenroth L, Rump A, Schröck E, Arnold N, Wimberger P, Kast K. Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study. Arch Gynecol Obstet 2017;295:1227-38. [PMID: 28324225 DOI: 10.1007/s00404-017-4330-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
95 Houlston RS, Peto J. The future of association studies of common cancers. Hum Genet 2003;112:434-5. [DOI: 10.1007/s00439-002-0902-4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 3.9] [Reference Citation Analysis]
96 Wernke K, Bellcross C, Gabram S, Ali N, Stanislaw C. Impact of Implementing B-RSTTM to Screen for Hereditary Breast and Ovarian Cancer on Risk Perception and Genetic Counseling Uptake Among Women in an Academic Safety Net Hospital. Clin Breast Cancer 2019;19:e547-55. [PMID: 31005475 DOI: 10.1016/j.clbc.2019.02.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, Rebbeck TR, Nathanson KL, Domchek SM. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Familial Cancer 2012;11:69-75. [DOI: 10.1007/s10689-011-9480-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
98 Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: what we know and what we need. Nat Med 2001;7:552-6. [PMID: 11329055 DOI: 10.1038/87876] [Cited by in Crossref: 287] [Cited by in F6Publishing: 245] [Article Influence: 14.4] [Reference Citation Analysis]
99 Powell K, Rakestraw J, Gupta S, Shou W, Lee K, Leitner O. Following NCCN guidelines within one hospital system in the United States: Comparison between cancer centers and genetic counselor utilization. J Genet Couns 2021. [PMID: 34369024 DOI: 10.1002/jgc4.1495] [Reference Citation Analysis]
100 Fresa A, Sica S. Should the BCRA1/2-mutations healthy carriers be valid candidates for hematopoietic stem cell donation? Hered Cancer Clin Pract 2021;19:22. [PMID: 33794974 DOI: 10.1186/s13053-021-00179-w] [Reference Citation Analysis]
101 Milne RL, Antoniou AC. Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. Endocr Relat Cancer 2016;23:T69-84. [PMID: 27528622 DOI: 10.1530/ERC-16-0277] [Cited by in Crossref: 33] [Cited by in F6Publishing: 15] [Article Influence: 6.6] [Reference Citation Analysis]
102 de Jonge MM, Mooyaart AL, Vreeswijk MP, de Kroon CD, van Wezel T, van Asperen CJ, Smit VT, Dekkers OM, Bosse T. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report. Eur J Cancer 2017;72:215-25. [PMID: 28049106 DOI: 10.1016/j.ejca.2016.11.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
103 Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M; Genes Environment and Melanoma Study Group. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005;97:1507-15. [PMID: 16234564 DOI: 10.1093/jnci/dji312] [Cited by in Crossref: 152] [Cited by in F6Publishing: 119] [Article Influence: 9.5] [Reference Citation Analysis]
104 Ou J, Wu T, Sijmons R, Ni D, Xu W, Upur H. Prevalence of BRCA1 and BRCA2 Germline Mutations in Breast Cancer Women of Multiple Ethnic Region in Northwest China. J Breast Cancer 2013;16:50-4. [PMID: 23593081 DOI: 10.4048/jbc.2013.16.1.50] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
105 Kwong A, Wong CH, Suen DT, Co M, Kurian AW, West DW, Ford JM. Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort. World J Surg 2012;36:702-13. [PMID: 22290208 DOI: 10.1007/s00268-011-1406-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
106 Landon G, Stewart J, Deavers M, Lu K, Sneige N. Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility. Gynecol Oncol 2012;125:683-6. [PMID: 22425664 DOI: 10.1016/j.ygyno.2012.03.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
107 de Boer M, Hauptmann M, Hijmering NJ, van Noesel CJM, Rakhorst HA, Meijers-Heijboer HEJ, de Boer JP, van der Hulst RRWJ, de Jong D, van Leeuwen FE. Increased prevalence of BRCA1/2 mutations in women with macrotextured breast implants and anaplastic large cell lymphoma of the breast. Blood 2020;136:1368-72. [PMID: 32452517 DOI: 10.1182/blood.2019004498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
108 Gronwald J, Byrski T, Huzarski T, Oszurek O, Janicka A, Szymanska-Pasternak J, Górski B, Menkiszak J, Rzepka-Górska I, Lubinski J. Hereditary breast and ovarian cancer. Hered Cancer Clin Pract 2008;6:88-98. [PMID: 19804604 DOI: 10.1186/1897-4287-6-2-88] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
109 Fu R, Harris EL, Helfand M, Nelson HD. Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach. Stat Med 2007;26:1775-87. [PMID: 17243094 DOI: 10.1002/sim.2811] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
110 van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011;34:71-88. [PMID: 21336636 DOI: 10.1007/s13402-011-0010-3] [Cited by in Crossref: 80] [Cited by in F6Publishing: 68] [Article Influence: 8.0] [Reference Citation Analysis]
111 Kan Z, Ding Y, Kim J, Jung HH, Chung W, Lal S, Cho S, Fernandez-Banet J, Lee SK, Kim SW, Lee JE, Choi YL, Deng S, Kim JY, Ahn JS, Sha Y, Mu XJ, Nam JY, Im YH, Lee S, Park WY, Nam SJ, Park YH. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nat Commun 2018;9:1725. [PMID: 29713003 DOI: 10.1038/s41467-018-04129-4] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 19.7] [Reference Citation Analysis]
112 Zubair M, Wang S, Ali N. Advanced Approaches to Breast Cancer Classification and Diagnosis. Front Pharmacol 2020;11:632079. [PMID: 33716731 DOI: 10.3389/fphar.2020.632079] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
113 Ponder B, Antoniou A, Dunning A, Easton D, Pharoah P. Polygenic Inherited Predisposition to Breast Cancer. Cold Spring Harbor Symposia on Quantitative Biology 2005;70:35-41. [DOI: 10.1101/sqb.2005.70.029] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
114 Rutter JL, Chatterjee N, Wacholder S, Struewing J. The HER2 I655V Polymorphism and Breast Cancer Risk in Ashkenazim: . Epidemiology 2003;14:694-700. [DOI: 10.1097/01.ede.0000083227.74669.7b] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
115 Solyom S, Pylkäs K, Winqvist R. Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families. Fam Cancer 2010;9:537-40. [PMID: 20567916 DOI: 10.1007/s10689-010-9360-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
116 Kim M, Kim YH, Kim YB, Kim J, Kim JW, Park MH, Park JH, Rhee JH, Lim MC, Hong JS. Bilateral salpingectomy to reduce the risk of ovarian/fallopian/peritoneal cancer in women at average risk: a position statement of the Korean Society of Obstetrics and Gynecology (KSOG). Obstet Gynecol Sci 2018;61:542-52. [PMID: 30254990 DOI: 10.5468/ogs.2018.61.5.542] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
117 Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 2018;19:169-80. [PMID: 29337092 DOI: 10.1016/S1470-2045(17)30891-4] [Cited by in Crossref: 124] [Cited by in F6Publishing: 73] [Article Influence: 41.3] [Reference Citation Analysis]
118 Hopper JL. Genetic epidemiology of female breast cancer. Semin Cancer Biol 2001;11:367-74. [PMID: 11562179 DOI: 10.1006/scbi.2001.0392] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
119 Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol 2013;7:567-79. [PMID: 23415752 DOI: 10.1016/j.molonc.2012.12.007] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 10.5] [Reference Citation Analysis]
120 Weitzel JN. The Genetics of Breast Cancer: What the Surgical Oncologist Needs to Know. Surg Oncol Clin N Am 2015;24:705-32. [PMID: 26363538 DOI: 10.1016/j.soc.2015.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
121 Collins JM, Isaacs C. Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer. Breast J 2020;26:1520-7. [PMID: 32652823 DOI: 10.1111/tbj.13970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Qiu H, Lin D. Roles of DNA mutation in the coding region and DNA methylation in the 5' flanking region of BRCA1 in canine mammary tumors. J Vet Med Sci 2016;78:943-9. [PMID: 26888582 DOI: 10.1292/jvms.15-0557] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
123 Nelson HD, Pappas M, Cantor A, Haney E, Holmes R. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2019;322:666-85. [PMID: 31429902 DOI: 10.1001/jama.2019.8430] [Cited by in Crossref: 43] [Cited by in F6Publishing: 24] [Article Influence: 21.5] [Reference Citation Analysis]
124 Yang R, Chen B, Hemminki K, Wappenschmidt B, Engel C, Sutter C, Ditsch N, Weber BH, Niederacher D, Arnold N, Meindl A, Bartram CR, Schmutzler RK, Burwinkel B. Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk. Breast Cancer Res Treat 2009;118:407-13. [PMID: 19229607 DOI: 10.1007/s10549-009-0348-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
125 Hadjisavvas A, Loizidou MA, Middleton N, Michael T, Papachristoforou R, Kakouri E, Daniel M, Papadopoulos P, Malas S, Marcou Y, Kyriacou K. An investigation of breast cancer risk factors in Cyprus: a case control study. BMC Cancer 2010;10:447. [PMID: 20727220 DOI: 10.1186/1471-2407-10-447] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
126 Lalloo F, Varley J, Moran A, Ellis D, O'dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A, Evans DG. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 2006;42:1143-50. [PMID: 16644204 DOI: 10.1016/j.ejca.2005.11.032] [Cited by in Crossref: 100] [Cited by in F6Publishing: 79] [Article Influence: 6.7] [Reference Citation Analysis]
127 Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002;9:941-3. [PMID: 12464584 DOI: 10.1007/BF02574510] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
128 Robson M. Breast Cancer Surveillance in Women with Hereditary Risk Due to BRCA1 or BRCA2 Mutations. Clinical Breast Cancer 2004;5:260-8. [DOI: 10.3816/cbc.2004.n.029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
129 Yadav S, Jinna S, Pereira-rodrigues O, Reeves A, Campian S, Sufka A, Zakalik D. Impact of preoperative BRCA1/2 testing on surgical decision making in patients with newly diagnosed breast cancer. Breast J 2018;24:541-8. [DOI: 10.1111/tbj.13007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
130 Hilbers FS, Luijsterburg MS, Wiegant WW, Meijers CM, Völker-Albert M, Boonen RA, van Asperen CJ, Devilee P, van Attikum H. Functional Analysis of Missense Variants in the Putative Breast Cancer Susceptibility Gene XRCC2. Hum Mutat 2016;37:914-25. [PMID: 27233470 DOI: 10.1002/humu.23019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
131 Morales S, De Mayo T, Gulppi FA, Gonzalez-Hormazabal P, Carrasco V, Reyes JM, Gómez F, Waugh E, Jara L. Genetic Variants in pre-miR-146a, pre-miR-499, pre-miR-125a, pre-miR-605, and pri-miR-182 Are Associated with Breast Cancer Susceptibility in a South American Population. Genes (Basel) 2018;9:E427. [PMID: 30135399 DOI: 10.3390/genes9090427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 5.7] [Reference Citation Analysis]
132 Rennert G, Dishon S, Rennert HS, Fares F. Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel: . European Journal of Cancer Prevention 2005;14:357-61. [DOI: 10.1097/00008469-200508000-00008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
133 Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, Burger CW, Brekelmans CT, Mourits MJ, de Bock GH, Gaarenstroom KN, van Boven HH, Mooij TM, Rookus MA. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007;96:1335-42. [PMID: 17426707 DOI: 10.1038/sj.bjc.6603725] [Cited by in Crossref: 102] [Cited by in F6Publishing: 75] [Article Influence: 7.3] [Reference Citation Analysis]
134 Pharoah PD, Guilford P, Caldas C; International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348-1353. [PMID: 11729114 DOI: 10.1053/gast.2001.29611] [Cited by in Crossref: 397] [Cited by in F6Publishing: 321] [Article Influence: 19.9] [Reference Citation Analysis]
135 Grignol VP, Agnese DM. Breast Cancer Genetics for the Surgeon: An Update on Causes and Testing Options. J Am Coll Surg 2016;222:906-14. [PMID: 26968323 DOI: 10.1016/j.jamcollsurg.2016.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
136 Kim H, Choi DH. Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer. J Breast Cancer 2013;16:357-65. [PMID: 24454456 DOI: 10.4048/jbc.2013.16.4.357] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 6.4] [Reference Citation Analysis]
137 Mavaddat N, Pharoah PD, Blows F, Driver KE, Provenzano E, Thompson D, Macinnis RJ, Shah M, Easton DF, Antoniou AC; SEARCH Team. Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res 2010;12:R10. [PMID: 20146796 DOI: 10.1186/bcr2476] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
138 Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ. Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med 2011;40:61-6. [PMID: 21146769 DOI: 10.1016/j.amepre.2010.09.027] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 10.4] [Reference Citation Analysis]
139 Kegelaers D, Merckx W, Odeurs P, van den Ende J, Blaumeiser B. Disclosure pattern and follow-up after the molecular diagnosis of BRCA/CHEK2 mutations. J Genet Couns 2014;23:254-61. [PMID: 24114282 DOI: 10.1007/s10897-013-9656-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
140 Hemminki K, Försti A, Lorenzo Bermejo J. Etiologic impact of known cancer susceptibility genes. Mutat Res 2008;658:42-54. [PMID: 17827054 DOI: 10.1016/j.mrrev.2007.07.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
141 Evans DGR, van Veen EM, Byers HJ, Wallace AJ, Ellingford JM, Beaman G, Santoyo-Lopez J, Aitman TJ, Eccles DM, Lalloo FI, Smith MJ, Newman WG. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer. Am J Hum Genet 2018;103:213-20. [PMID: 30075112 DOI: 10.1016/j.ajhg.2018.07.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 17.5] [Reference Citation Analysis]
142 El-tanani MK, Campbell FC, Crowe P, Erwin P, Harkin DP, Pharoah P, Ponder B, Rudland PS. BRCA1 Suppresses Osteopontin-mediated Breast Cancer. Journal of Biological Chemistry 2006;281:26587-601. [DOI: 10.1074/jbc.m604403200] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
143 Ryan ST, Nguyen V, Bree KK, Holst DD, Kader AK. Germline genetics in localized prostate cancer. Curr Opin Urol 2019;29:326-33. [PMID: 31116139 DOI: 10.1097/MOU.0000000000000648] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Palmero EI, Caleffi M, Schüler-Faccini L, Roth FL, Kalakun L, Netto CB, Skonieski G, Giacomazzi J, Weber B, Giugliani R, Camey SA, Ashton-Prolla P. Population prevalence of hereditary breast cancer phenotypes and implementation of a genetic cancer risk assessment program in southern Brazil. Genet Mol Biol 2009;32:447-55. [PMID: 21637504 DOI: 10.1590/S1415-47572009005000058] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
145 Pölsler L, Fiegl H, Wimmer K, Oberaigner W, Amberger A, Traunfellner P, Morscher RJ, Weber I, Fauth C, Wernstedt A, Sperner-Unterweger B, Oberguggenberger A, Hubalek M, Marth C, Zschocke J. High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing. Eur J Hum Genet 2016;24:258-62. [PMID: 26014432 DOI: 10.1038/ejhg.2015.108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
146 Aretini P, D'andrea E, Pasini B, Viel A, Costantini RM, Cortesi L, Ricevuto E, Agata S, Bisegna R, Boiocchi M, Caligo MA, Chieco-bianchi L, Cipollini G, Crucianelli R, D'amico C, Federico M, Ghimenti C, De Giacomi C, De Nicolo A, Puppa LD, Ferrari S, Ficorella C, Iandolo D, Manoukian S, Marchetti P, Marroni F, Menin C, Montagna M, Ottini L, Pensotti V, Pierotti M, Radice P, Santarosa M, Silingardi V, Turchetti D, Bevilacqua G, Presciuttini S. Different Expressivity of BRCA1 and BRCA2: Analysis of 179 Italian Pedigrees with Identified Mutation. Breast Cancer Res Treat 2003;81:71-9. [DOI: 10.1023/a:1025428807472] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
147 Evans DG, Astley S, Stavrinos P, Harkness E, Donnelly LS, Dawe S, Jacob I, Harvie M, Cuzick J, Brentnall A, Wilson M, Harrison F, Payne K, Howell A. Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. Programme Grants Appl Res 2016;4:1-210. [DOI: 10.3310/pgfar04110] [Cited by in Crossref: 40] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
148 Loizzi V, Cicinelli E, Santamaria F, Murgia F, Minicucci V, Resta L, Resta N, Natalicchio MI, Ranieri G, Cormio G. BRCAmut and "founder effect": a prospective study in a single academic institution. Oncotarget 2018;9:22353-8. [PMID: 29854283 DOI: 10.18632/oncotarget.24959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
149 Michl J, Zimmer J, Tarsounas M. Interplay between Fanconi anemia and homologous recombination pathways in genome integrity. EMBO J 2016;35:909-23. [PMID: 27037238 DOI: 10.15252/embj.201693860] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 20.6] [Reference Citation Analysis]
150 Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80-7. [PMID: 19141781 DOI: 10.1093/jnci/djn442] [Cited by in Crossref: 578] [Cited by in F6Publishing: 412] [Article Influence: 48.2] [Reference Citation Analysis]
151 Kawahara M, Sakayori M, Shiraishi K, Nomizu T, Takeda M, Abe R, Ohuchi N, Takenoshita S, Ishioka C. Identification and evaluation of 55 genetic variations in the BRCA1 and the BRCA2 genes of patients from 50 Japanese breast cancer families. J Hum Genet 2004;49:391-5. [PMID: 15168169 DOI: 10.1007/s10038-004-0160-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
152 Stemke-Hale K, Hennessy B, Mills GB, Mitra R. Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein. Curr Oncol Rep 2006;8:484-91. [PMID: 17040626 DOI: 10.1007/s11912-006-0078-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
153 Hall MJ, Olopade OI. Disparities in Genetic Testing: Thinking Outside the BRCA Box. JCO 2006;24:2197-203. [DOI: 10.1200/jco.2006.05.5889] [Cited by in Crossref: 112] [Cited by in F6Publishing: 64] [Article Influence: 7.5] [Reference Citation Analysis]
154 Pasanisi P, Bruno E, Venturelli E, Manoukian S, Barile M, Peissel B, De Giacomi C, Bonanni B, Berrino J, Berrino F. Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families. Fam Cancer 2011;10:521-8. [PMID: 21455766 DOI: 10.1007/s10689-011-9437-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
155 Docherty Z, Georgiou A, Langman C, Kesterton I, Rose S, Camplejohn R, Ball J, Barwell J, Gilchrist R, Pangon L, Berg J, Hodgson S. Is chromosome radiosensitivity and apoptotic response to irradiation correlated with cancer susceptibility? International Journal of Radiation Biology 2009;83:1-12. [DOI: 10.1080/09553000600932968] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
156 Kurian AW, Antoniou AC, Domchek SM. Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. American Society of Clinical Oncology Educational Book 2016. [DOI: 10.1200/edbk_158817] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
157 Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer. 2010;10:353-361. [PMID: 20414203 DOI: 10.1038/nrc2840] [Cited by in Crossref: 155] [Cited by in F6Publishing: 129] [Article Influence: 14.1] [Reference Citation Analysis]
158 Ahn PH, Vu HT, Lannin D, Obedian E, DiGiovanna MP, Burtness B, Haffty BG. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 2005;23:17-23. [PMID: 15545666 DOI: 10.1200/JCO.2005.09.048] [Cited by in Crossref: 74] [Cited by in F6Publishing: 9] [Article Influence: 4.4] [Reference Citation Analysis]
159 de Kermadec E, Thomassin I, Daraï E, Kolanska K, Chabbert-Buffet N. [Impact of the menstrual cycle on the quality of interpretation of the MRI result in the follow-up of women at genetic risk for breast]. Gynecol Obstet Fertil Senol 2021:S2468-7189(21)00075-1. [PMID: 33771738 DOI: 10.1016/j.gofs.2021.03.024] [Reference Citation Analysis]
160 Ramon Y Cajal T, Torres A, Alonso C, Fisas D, Ojeda B, Boguña I, Prat J, Baiget M, Barnadas A. Risk factors associated with the occurrence of breast cancer after bilateral salpingo-oophorectomy in high-risk women. Cancer Epidemiol 2011;35:78-82. [PMID: 20638925 DOI: 10.1016/j.canep.2010.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
161 Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, Bolla MK, Shu XO, Lu Y, Cai Q, Al-Ejeh F, Rozali E, Wang Q, Dennis J, Li B, Zeng C, Feng H, Gusev A, Barfield RT, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Barrdahl M, Baynes C, Beckmann MW, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Brinton L, Broberg P, Brucker SY, Burwinkel B, Caldés T, Canzian F, Carter BD, Castelao JE, Chang-Claude J, Chen X, Cheng TD, Christiansen H, Clarke CL, Collée M, Cornelissen S, Couch FJ, Cox D, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, Dos-Santos-Silva I, Dumont M, Dwek M, Eccles DM, Eilber U, Eliassen AH, Engel C, Eriksson M, Fachal L, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Closas M, Gaudet MM, Ghoussaini M, Giles GG, Goldberg MS, Goldgar DE, González-Neira A, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hallberg E, Hamann U, Harrington P, Hein A, Hicks B, Hillemanns P, Hollestelle A, Hoover RN, Hopper JL, Huang G, Humphreys K, Hunter DJ, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones ME, Jung A, Kaaks R, Kerin MJ, Khusnutdinova E, Kosma VM, Kristensen VN, Lambrechts D, Le Marchand L, Li J, Lindström S, Lissowska J, Lo WY, Loibl S, Lubinski J, Luccarini C, Lux MP, MacInnis RJ, Maishman T, Kostovska IM, Mannermaa A, Manson JE, Margolin S, Mavroudis D, Meijers-Heijboer H, Meindl A, Menon U, Meyer J, Mulligan AM, Neuhausen SL, Nevanlinna H, Neven P, Nielsen SF, Nordestgaard BG, Olopade OI, Olson JE, Olsson H, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prentice R, Presneau N, Pylkäs K, Rack B, Radice P, Rahman N, Rennert G, Rennert HS, Rhenius V, Romero A, Romm J, Rudolph A, Saloustros E, Sandler DP, Sawyer EJ, Schmidt MK, Schmutzler RK, Schneeweiss A, Scott RJ, Scott CG, Seal S, Shah M, Shrubsole MJ, Smeets A, Southey MC, Spinelli JJ, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper W, Taylor JA, Terry MB, Tessier DC, Thomas A, Thöne K, Tollenaar RAEM, Torres D, Truong T, Untch M, Vachon C, Van Den Berg D, Vincent D, Waisfisz Q, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett WC, Winqvist R, Wolk A, Xia L, Yang XR, Ziogas A, Ziv E, Dunning AM, Pharoah PDP, Simard J, Milne RL, Edwards SL, Kraft P, Easton DF, Chenevix-Trench G, Zheng W; NBCS Collaborators., kConFab/AOCS Investigators. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nat Genet 2018;50:968-78. [PMID: 29915430 DOI: 10.1038/s41588-018-0132-x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 58] [Article Influence: 29.3] [Reference Citation Analysis]
162 Lang GT, Shi JX, Hu X, Zhang CH, Shan L, Song CG, Zhuang ZG, Cao AY, Ling H, Yu KD, Li S, Sun MH, Zhou XY, Huang W, Shao ZM. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing. Int J Cancer 2017;141:129-42. [PMID: 28294317 DOI: 10.1002/ijc.30692] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 10.5] [Reference Citation Analysis]
163 Sun B, Yeh J. Onco-fertility and personalized testing for potential for loss of ovarian reserve in patients undergoing chemotherapy: proposed next steps for development of genetic testing to predict changes in ovarian reserve. Fertil Res Pract 2021;7:13. [PMID: 34193292 DOI: 10.1186/s40738-021-00105-7] [Reference Citation Analysis]
164 Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O'Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World J Gastrointest Oncol 2019;11:102-16. [PMID: 30788038 DOI: 10.4251/wjgo.v11.i2.102] [Reference Citation Analysis]
165 Masood S. The role of pathologists in recognition of morphologic and biologic features of genetically mutated breast cancer. Breast J 2020;26:1583-8. [PMID: 32845077 DOI: 10.1111/tbj.14012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Gong G, Whittemore AS. Optimal designs for estimating penetrance of rare mutations of a disease-susceptibility gene. Genet Epidemiol 2003;24:173-80. [PMID: 12652521 DOI: 10.1002/gepi.10219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
167 Guirouilh-Barbat JK, Wilhelm T, Lopez BS. AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers. Oncotarget 2010;1:691-9. [PMID: 21321378 DOI: 10.18632/oncotarget.101202] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
168 Chew W, Moorakonda RB, Courtney E, Soh H, Li ST, Chen Y, Shaw T, Allen JC, Evans DGR, Ngeow J. Evaluation of the relative effectiveness of the 2017 updated Manchester scoring system for predicting BRCA1/2 mutations in a Southeast Asian country. J Med Genet 2018;55:344-50. [PMID: 29275357 DOI: 10.1136/jmedgenet-2017-105073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
169 Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, Luccarini C, Munday H, Perkins B, Smith P, Pharoah PD, Wareham NJ, Easton DF, Ponder BA, Dunning AM. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 2006;15:1-10. [PMID: 16306136 DOI: 10.1093/hmg/ddi398] [Cited by in Crossref: 113] [Cited by in F6Publishing: 114] [Article Influence: 7.1] [Reference Citation Analysis]
170 Dossus L, Benusiglio PR. Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res 2015;17:37. [PMID: 25848941 DOI: 10.1186/s13058-015-0546-7] [Cited by in Crossref: 70] [Cited by in F6Publishing: 52] [Article Influence: 11.7] [Reference Citation Analysis]
171 Rhiem K, Foth D, Wappenschmidt B, Gevensleben H, Büttner R, Ulrich U, Schmutzler RK. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 2011;283:623-7. [PMID: 20428881 DOI: 10.1007/s00404-010-1476-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
172 Li W, Amei A, Bui F, Norouzifar S, Lu L, Wang Z. Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival. Cancers (Basel) 2021;13:2879. [PMID: 34207556 DOI: 10.3390/cancers13122879] [Reference Citation Analysis]
173 de Mestier L, Danset J, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. Endocrine-Related Cancer 2016;23:T57-67. [DOI: 10.1530/erc-16-0269] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
174 Henouda S, Bensalem A, Reggad R, Serrar N, Rouabah L, Pujol P. Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer. Dis Markers 2016;2016:7869095. [PMID: 26997744 DOI: 10.1155/2016/7869095] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
175 Gumaste PV, Penn LA, Cymerman RM, Kirchhoff T, Polsky D, McLellan B. Skin cancer risk in BRCA1/2 mutation carriers. Br J Dermatol 2015;172:1498-506. [PMID: 25524463 DOI: 10.1111/bjd.13626] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
176 Long Roche KC, Abu-Rustum NR, Nourmoussavi M, Zivanovic O. Risk-reducing salpingectomy: Let us be opportunistic. Cancer 2017;123:1714-20. [PMID: 28334425 DOI: 10.1002/cncr.30528] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
177 Bhatia S, Drake DM, Miller L, Wells PG. Oxidative stress and DNA damage in the mechanism of fetal alcohol spectrum disorders. Birth Defects Res 2019;111:714-48. [PMID: 31033255 DOI: 10.1002/bdr2.1509] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
178 Schmitz-Dräger BJ, Schöffski O, Marberger M, Sahin S, Schmid HP. Risk adapted chemoprevention for prostate cancer: an option? Recent Results Cancer Res 2014;202:79-91. [PMID: 24531781 DOI: 10.1007/978-3-642-45195-9_10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
179 Biglia N, Mariani L, Ponzone R, Sismondi P. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1–2 mutation carriers. Maturitas 2008;60:71-7. [DOI: 10.1016/j.maturitas.2008.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
180 Ayme A, Viassolo V, Rapiti E, Fioretta G, Schubert H, Bouchardy C, Chappuis PO, Benhamou S. Determinants of genetic counseling uptake and its impact on breast cancer outcome: a population-based study. Breast Cancer Res Treat 2014;144:379-89. [PMID: 24519389 DOI: 10.1007/s10549-014-2864-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
181 Benusiglio PR, Lesueur F, Luccarini C, McIntosh J, Luben RN, Smith P, Dunning A, Easton DF, Ponder BA, Pharoah PD. Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs. BMC Cancer 2005;5:81. [PMID: 16029503 DOI: 10.1186/1471-2407-5-81] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
182 Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28:2404-2410. [PMID: 20368571 DOI: 10.1200/jco.2009.24.2495] [Cited by in Crossref: 129] [Cited by in F6Publishing: 67] [Article Influence: 11.7] [Reference Citation Analysis]
183 Gomy I, Diz Mdel P. Hereditary cancer risk assessment: insights and perspectives for the Next-Generation Sequencing era. Genet Mol Biol 2016;39:184-8. [PMID: 27192130 DOI: 10.1590/1678-4685-GMB-2014-0346] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
184 Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF; EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013;105:812-22. [PMID: 23628597 DOI: 10.1093/jnci/djt095] [Cited by in Crossref: 548] [Cited by in F6Publishing: 412] [Article Influence: 68.5] [Reference Citation Analysis]
185 Oberguggenberger A, Sztankay M, Morscher RJ, Sperner-Unterweger B, Weber I, Hubalek M, Kemmler G, Zschocke J, Martini C, Egle D, Dünser M, Gamper E, Meraner V. Psychosocial outcomes and counselee satisfaction following genetic counseling for hereditary breast and ovarian cancer: A patient-reported outcome study. J Psychosom Res 2016;89:39-45. [PMID: 27663109 DOI: 10.1016/j.jpsychores.2016.08.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
186 Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130. [PMID: 12677558 DOI: 10.1086/375033] [Cited by in Crossref: 2359] [Cited by in F6Publishing: 1871] [Article Influence: 131.1] [Reference Citation Analysis]
187 Palma M, Ristori E, Ricevuto E, Giannini G, Gulino A. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers. Crit Rev Oncol Hematol 2006;57:1-23. [PMID: 16337408 DOI: 10.1016/j.critrevonc.2005.05.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
188 Wendt C, Lindblom A, Arver B, von Wachenfeldt A, Margolin S. Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden. Hered Cancer Clin Pract 2015;13:15. [PMID: 26082817 DOI: 10.1186/s13053-015-0036-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
189 Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng C, Wong JB; US Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA -Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2019;322:652. [DOI: 10.1001/jama.2019.10987] [Cited by in Crossref: 115] [Cited by in F6Publishing: 68] [Article Influence: 57.5] [Reference Citation Analysis]
190 Freitas AC, Opinião A, Fragoso S, Nunes H, Santos M, Clara A, Bento S, Luis A, Silva J, Moura C, Filipe B, Machado P, Santos S, André S, Rodrigues P, Parreira J, Vaz F. Men seeking counselling in a Breast Cancer Risk Evaluation Clinic. Ecancermedicalscience 2018;12:804. [PMID: 29456621 DOI: 10.3332/ecancer.2018.804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
191 McInerney NM, Miller N, Rowan A, Colleran G, Barclay E, Curran C, Kerin MJ, Tomlinson IP, Sawyer E. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res Treat 2010;121:203-10. [PMID: 19763819 DOI: 10.1007/s10549-009-0540-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
192 Chen W, Wang W, Zhu B, Guo H, Sun Y, Ming J, Shen N, Li Z, Wang Z, Liu L, Cai B, Duan J, Li J, Liu C, Zhong R, Hu W, Huang T, Miao X. A functional variant rs1820453 in YAP1 and breast cancer risk in Chinese population. PLoS One 2013;8:e79056. [PMID: 24223879 DOI: 10.1371/journal.pone.0079056] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
193 Sun Y, Li Y, Wu J, Tian H, Liu H, Fang Y, Li Y, Yu F. Nomograms for prediction of overall and cancer-specific survival in young breast cancer. Breast Cancer Res Treat 2020;184:597-613. [PMID: 32886273 DOI: 10.1007/s10549-020-05870-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
194 Morales S, Gulppi F, Gonzalez-Hormazabal P, Fernandez-Ramires R, Bravo T, Reyes JM, Gomez F, Waugh E, Jara L. Association of single nucleotide polymorphisms in Pre-miR-27a, Pre-miR-196a2, Pre-miR-423, miR-608 and Pre-miR-618 with breast cancer susceptibility in a South American population. BMC Genet 2016;17:109. [PMID: 27421647 DOI: 10.1186/s12863-016-0415-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
195 Berrino J, Berrino F, Francisci S, Peissel B, Azzollini J, Pensotti V, Radice P, Pasanisi P, Manoukian S. Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability. Fam Cancer 2015;14:117-28. [PMID: 25373702 DOI: 10.1007/s10689-014-9766-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
196 Guo F, Scholl M, Fuchs EL, Berenson AB, Kuo YF. BRCA testing in unaffected young women in the United States, 2006-2017. Cancer 2020;126:337-43. [PMID: 31568561 DOI: 10.1002/cncr.32536] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
197 Chang-Claude J, Dunning A, Schnitzbauer U, Galmbacher P, Tee L, Wjst M, Chalmers J, Zemzoum I, Harbeck N, Pharoah PD, Hahn H. The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk. Int J Cancer 2003;103:779-83. [PMID: 12516098 DOI: 10.1002/ijc.10889] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 2.7] [Reference Citation Analysis]
198 Kim EK, Park SY, Kim SW. Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients. J Pathol Transl Med 2020;54:265-75. [PMID: 32397691 DOI: 10.4132/jptm.2020.04.07] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Chavarri-Guerra Y, Blazer KR, Weitzel JN. Genetic Cancer Risk Assessment for Breast Cancer in Latin America. Rev Invest Clin 2017;69:94-102. [PMID: 28453507 DOI: 10.24875/ric.17002195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
200 Chang ET, Milne RL, Phillips KA, Figueiredo JC, Sangaramoorthy M, Keegan TH, Andrulis IL, Hopper JL, Goodwin PJ, O'Malley FP, Weerasooriya N, Apicella C, Southey MC, Friedlander ML, Giles GG, Whittemore AS, West DW, John EM. Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry. Breast Cancer Res Treat 2009;117:167-76. [PMID: 19034644 DOI: 10.1007/s10549-008-0255-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
201 Verhagen CVM, Vossen DM, Borgmann K, Hageman F, Grénman R, Verwijs-Janssen M, Mout L, Kluin RJC, Nieuwland M, Severson TM, Velds A, Kerkhoven R, O'Connor MJ, van der Heijden M, van Velthuysen ML, Verheij M, Wreesmann VB, Wessels LFA, van den Brekel MWM, Vens C. Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma. Oncotarget 2018;9:18198-213. [PMID: 29719599 DOI: 10.18632/oncotarget.24797] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
202 Griffiths SE, Lopes T, Edmondson RJ. The role of prophylactic salpingo-oophorectomy in women who carry mutations of the BRCA genes. The Obstetrician & Gynaecologist 2005;7:23-7. [DOI: 10.1576/toag.7.1.023.27038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
203 Samuelson DJ, Hesselson SE, Aperavich BA, Zan Y, Haag JD, Trentham-Dietz A, Hampton JM, Mau B, Chen KS, Baynes C, Khaw KT, Luben R, Perkins B, Shah M, Pharoah PD, Dunning AM, Easton DF, Ponder BA, Gould MN. Rat Mcs5a is a compound quantitative trait locus with orthologous human loci that associate with breast cancer risk. Proc Natl Acad Sci U S A 2007;104:6299-304. [PMID: 17404222 DOI: 10.1073/pnas.0701687104] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis]
204 Humar B, Toro T, Graziano F, Müller H, Dobbie Z, Kwang-Yang H, Eng C, Hampel H, Gilbert D, Winship I. Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. Hum Mutat. 2002;19:518-525. [PMID: 11968084 DOI: 10.1002/humu.10067] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 2.3] [Reference Citation Analysis]
205 Constantinou P, Tischkowitz M. Genetics of gynaecological cancers. Best Practice & Research Clinical Obstetrics & Gynaecology 2017;42:114-24. [DOI: 10.1016/j.bpobgyn.2017.01.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
206 Maxwell KN, Domchek SM. Familial Breast Cancer Risk. Curr Breast Cancer Rep 2013;5:170-82. [DOI: 10.1007/s12609-013-0117-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
207 Blankenship L, Lyons YA, Dao Campi H, Valente PT, Barnes L, Kost ER. A rectovaginal septum mass in a BRCA1 positive patient years after risk reducing surgery: A case report. Gynecol Oncol Rep 2021;36:100772. [PMID: 34026998 DOI: 10.1016/j.gore.2021.100772] [Reference Citation Analysis]
208 Tang L, Chen F, Wang H, Hu X, Dai X, Mao J, Shen Z, Wu Y, Wang S, Hai J, Yan G, Li H, Huang J. Haplotype analysis of eight genes of the monoubiquitinated FANCD2–DNA damage–repair pathway in breast cancer patients. Cancer Epidemiology 2013;37:311-7. [DOI: 10.1016/j.canep.2012.12.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
209 Chappuis P, Hamel N, Paradis A, Deschênes J, Robidoux A, Potvin C, Cantin J, Tonin P, Ghadirian P, Foulkes W. Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer: BRCA1 and BRCA2 mutations in French Canadian women with breast cancer. Clinical Genetics 2001;59:418-23. [DOI: 10.1034/j.1399-0004.2001.590606.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
210 Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, Lidereau R, Mikaélian I, Mazoyer S. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med. 2011;3:279-290. [PMID: 21472990 DOI: 10.1002/emmm.201100136] [Cited by in Crossref: 173] [Cited by in F6Publishing: 164] [Article Influence: 17.3] [Reference Citation Analysis]
211 Tan DS, Marchiò C, Reis-Filho JS. Hereditary breast cancer: from molecular pathology to tailored therapies. J Clin Pathol 2008;61:1073-82. [PMID: 18682420 DOI: 10.1136/jcp.2008.057950] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
212 Mckean-cowdin R, Spencer Feigelson H, Xia LY, Pearce CL, Thomas DC, Stram DO, Henderson BE. BRCA1 variants in a family study of African-American and Latina women. Hum Genet 2005;116:497-506. [DOI: 10.1007/s00439-004-1240-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
213 Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008;299:194-201. [PMID: 18182601 DOI: 10.1001/jama.2007.55-a] [Cited by in Crossref: 169] [Cited by in F6Publishing: 171] [Article Influence: 13.0] [Reference Citation Analysis]
214 Wong-brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, Rudnicka H, Lubinski J, Scott RJ. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat 2015;150:71-80. [DOI: 10.1007/s10549-015-3293-7] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
215 Rasmussen CB, Kjær SK, Ejlertsen B, Andersson M, Jensen M, Christensen J, Langballe R, Mellemkjær L. Incidence of metachronous contralateral breast cancer in Denmark 1978–2009. International Journal of Epidemiology 2014;43:1855-64. [DOI: 10.1093/ije/dyu202] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
216 Hughes DJ, Ginolhac SM, Coupier I, Barjhoux L, Gaborieau V, Bressac-de-paillerets B, Chompret A, Bignon Y, Uhrhammer N, Lasset C, Giraud S, Sobol H, Hardouin A, Berthet P, Peyrat J, Fournier J, Nogues C, Lidereau R, Muller D, Fricker J, Longy M, Toulas C, Guimbaud R, Yannoukakos D, Mazoyer S, Lynch HT, Lenoir GM, Goldgar DE, Stoppa-lyonnet D, Sinilnikova OM. Breast cancer risk inBRCA1 andBRCA2 mutation carriers and polyglutamine repeat length in theAIB1 gene. Int J Cancer 2005;117:230-3. [DOI: 10.1002/ijc.21176] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
217 Trivers KF, Rodriguez JL, Cox SL, Crane BE, Duquette D. The Activities and Impact of State Programs to Address Hereditary Breast and Ovarian Cancer, 2011-2014. Healthcare (Basel) 2015;3:948-63. [PMID: 27417805 DOI: 10.3390/healthcare3040948] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
218 Pharoah PD, Ponder BA. The genetics of ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 2002;16:449-68. [DOI: 10.1053/beog.2002.0296] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 2.5] [Reference Citation Analysis]
219 Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967-975. [PMID: 20810374 DOI: 10.1001/jama.2010.1237] [Cited by in Crossref: 931] [Cited by in F6Publishing: 671] [Article Influence: 84.6] [Reference Citation Analysis]
220 Kushnir A, Laitman Y, Shimon SP, Berger R, Friedman E. Germline mutations in RAD51C in Jewish high cancer risk families. Breast Cancer Res Treat 2012;136:869-74. [DOI: 10.1007/s10549-012-2317-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
221 El Saghir NS, Zgheib NK, Assi HA, Khoury KE, Bidet Y, Jaber SM, Charara RN, Farhat RA, Kreidieh FY, Decousus S, Romero P, Nemer GM, Salem Z, Shamseddine A, Tfayli A, Abbas J, Jamali F, Seoud M, Armstrong DK, Bignon YJ, Uhrhammer N. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer. Oncologist 2015;20:357-64. [PMID: 25777348 DOI: 10.1634/theoncologist.2014-0364] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
222 Robles-d�az L, Goldfrank DJ, Kauff ND, Robson M, Offit K. Hereditary ovarian cancer in Ashkenazi Jews. Familial Cancer 2004;3:259-64. [DOI: 10.1007/s10689-004-9552-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
223 Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007;7:937-48. [PMID: 18034184 DOI: 10.1038/nrc2054] [Cited by in Crossref: 279] [Cited by in F6Publishing: 246] [Article Influence: 21.5] [Reference Citation Analysis]
224 Gong Y, Ji P, Sun W, Jiang YZ, Hu X, Shao ZM. Development and Validation of Nomograms for Predicting Overall and Breast Cancer-Specific Survival in Young Women with Breast Cancer: A Population-Based Study. Transl Oncol 2018;11:1334-42. [PMID: 30189361 DOI: 10.1016/j.tranon.2018.08.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
225 Pharoah PDP. Genetic Susceptibility, Predicting Risk and Preventing Cancer. In: Senn H, Morant R, editors. Tumor Prevention and Genetics. Berlin: Springer Berlin Heidelberg; 2003. pp. 7-18. [DOI: 10.1007/978-3-642-55647-0_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
226 Kurian AW, Hughes E, Handorf EA, Gutin A, Allen B, Hartman A, Hall MJ. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. JCO Precision Oncology 2017. [DOI: 10.1200/po.16.00066] [Cited by in Crossref: 38] [Article Influence: 9.5] [Reference Citation Analysis]
227 Holman LL, Lu KH. Genetic risk and gynecologic cancers. Hematol Oncol Clin North Am 2012;26:13-29. [PMID: 22244659 DOI: 10.1016/j.hoc.2011.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
228 Hsu CR, Lu TM, Chin LW, Yang CC. Possible DNA viral factors of human breast cancer. Cancers (Basel) 2010;2:498-512. [PMID: 24281079 DOI: 10.3390/cancers2020498] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
229 Driver KE, Song H, Lesueur F, Ahmed S, Barbosa-Morais NL, Tyrer JP, Ponder BA, Easton DF, Pharoah PD, Dunning AM; Studies in Epidemiology and Risks of Cancer Heredity (SEARCH) Team. Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis 2008;29:333-41. [PMID: 18174243 DOI: 10.1093/carcin/bgm284] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
230 Gronwald J, Jauch A, Cybulski C, Schoell B, Böhm-Steuer B, Lener M, Grabowska E, Górski B, Jakubowska A, Domagała W, Chosia M, Scott RJ, Lubiński J. Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization. Int J Cancer 2005;114:230-6. [PMID: 15540206 DOI: 10.1002/ijc.20723] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
231 Piombino C, Mastrolia I, Omarini C, Candini O, Dominici M, Piacentini F, Toss A. The Role of Exosomes in Breast Cancer Diagnosis. Biomedicines 2021;9:312. [PMID: 33803776 DOI: 10.3390/biomedicines9030312] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Coupier I, Cousin P, Hughes D, Legoix-né P, Trehin A, Sinilnikova OM, Stoppa-lyonnet D. BAP1 and Breast Cancer Risk. Familial Cancer 2005;4:273-7. [DOI: 10.1007/s10689-005-2833-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
233 Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers. Cancer Sci 2018;109:166-73. [PMID: 29047188 DOI: 10.1111/cas.13426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
234 Thomas A, Rhoads A, Pinkerton E, Schroeder MC, Conway KM, Hundley WG, McNally LR, Oleson J, Lynch CF, Romitti PA. Incidence and Survival Among Young Women With Stage I-III Breast Cancer: SEER 2000-2015. JNCI Cancer Spectr 2019;3:pkz040. [PMID: 31392297 DOI: 10.1093/jncics/pkz040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
235 West JG, Weitzel JN, Tao ML, Carpenter M, West JE, Fanning C. BRCA Mutations and the Risk of Angiosarcoma After Breast Cancer Treatment. Clinical Breast Cancer 2008;8:533-7. [DOI: 10.3816/cbc.2008.n.066] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
236 S. Chapman J, Roddy E, Panighetti A, Hwang S, Crawford B, Powell B, Chen L. Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer. Clinical Breast Cancer 2016;16:494-9. [DOI: 10.1016/j.clbc.2016.06.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
237 Daum H, Peretz T, Laufer N. BRCA mutations and reproduction. Fertil Steril 2018;109:33-8. [PMID: 29307397 DOI: 10.1016/j.fertnstert.2017.12.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
238 Cybulski C, Nazarali S, Narod SA. Multiple primary cancers as a guide to heritability. Int J Cancer. 2014;135:1756-1763. [PMID: 24945890 DOI: 10.1002/ijc.28988] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
239 Wildschut HI, Peters TJ, Weiner CP. Screening in women's health, with emphasis on fetal Down's syndrome, breast cancer and osteoporosis. Hum Reprod Update 2006;12:499-512. [PMID: 16807275 DOI: 10.1093/humupd/dml027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
240 Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet 2018;19:581-90. [DOI: 10.1038/s41576-018-0018-x] [Cited by in Crossref: 491] [Cited by in F6Publishing: 339] [Article Influence: 163.7] [Reference Citation Analysis]
241 Véron A, Blein S, Cox DG. Genome-wide association studies and the clinic: a focus on breast cancer. Biomarkers in Medicine 2014;8:287-96. [DOI: 10.2217/bmm.13.121] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
242 Yurgelun MB, Hiller E, Garber JE. Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing? JCO 2015;33:3092-5. [DOI: 10.1200/jco.2015.60.8596] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
243 Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat 2013;137:579-87. [PMID: 23224237 DOI: 10.1007/s10549-012-2365-1] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 8.6] [Reference Citation Analysis]
244 Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up of BRCA1 Mutation Carriers. JCO 2005;23:8629-35. [DOI: 10.1200/jco.2005.02.9199] [Cited by in Crossref: 108] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
245 Liede A, Narod SA. Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat 2002;20:413-24. [PMID: 12442265 DOI: 10.1002/humu.10154] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 4.9] [Reference Citation Analysis]
246 Xu Y, Diao L, Chen Y, Liu Y, Wang C, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Deng D, Narod SA, Xie Y. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. Ann Oncol 2013;24:1498-505. [PMID: 23406733 DOI: 10.1093/annonc/mdt011] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
247 Armaou S, Pertesi M, Fostira F, Thodi G, Athanasopoulos PS, Kamakari S, Athanasiou A, Gogas H, Yannoukakos D, Fountzilas G, Konstantopoulou I. Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases. Br J Cancer 2009;101:32-7. [PMID: 19491894 DOI: 10.1038/sj.bjc.6605115] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
248 Gerdes A, Cruger D, Thomassen M, Kruse T. Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families: Evaluation of two different models. Clinical Genetics 2006;69:171-8. [DOI: 10.1111/j.1399-0004.2006.00568.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
249 Shi J, Tong J, Cai S, Qu X, Liu Y. Correlation of the BACH1 Pro919Ser polymorphism with breast cancer risk: A literature-based meta-analysis and meta-regression analysis. Exp Ther Med 2013;6:435-44. [PMID: 24137204 DOI: 10.3892/etm.2013.1148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
250 Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.J Clin Oncol. 2020;38:4274-4282. [PMID: 33119476 DOI: 10.1200/JCO.20.02151] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 38.0] [Reference Citation Analysis]
251 Wang F, Fang Q, Ge Z, Yu N, Xu S, Fan X. Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review. Mol Biol Rep 2012;39:2109-18. [DOI: 10.1007/s11033-011-0958-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
252 Kotnik U, Peterlin B, Lovrecic L. Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines. BMC Cancer 2021;21:665. [PMID: 34082720 DOI: 10.1186/s12885-021-08400-8] [Reference Citation Analysis]
253 Hilbers FS, Vreeswijk MP, van Asperen CJ, Devilee P. The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation? Clin Genet 2013;84:407-14. [PMID: 24025038 DOI: 10.1111/cge.12256] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
254 Smith P, McGuffog L, Easton DF, Mann GJ, Pupo GM, Newman B, Chenevix-Trench G, Szabo C, Southey M, Renard H, Odefrey F, Lynch H, Stoppa-Lyonnet D, Couch F, Hopper JL, Giles GG, McCredie MR, Buys S, Andrulis I, Senie R, Goldgar DE, Oldenburg R, Kroeze-Jansema K, Kraan J, Meijers-Heijboer H, Klijn JG, van Asperen C, van Leeuwen I, Vasen HF, Cornelisse CJ, Devilee P, Baskcomb L, Seal S, Barfoot R, Mangion J, Hall A, Edkins S, Rapley E, Wooster R, Chang-Claude J, Eccles D, Evans DG, Futreal P, Nathanson KL, Weber BL, Rahman N, Stratton MR; kConFab Investigators., BCFS, BRCAX Collaborators Group., Breast Cancer Susceptibility Collaboration (UK). A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 2006;45:646-55. [PMID: 16575876 DOI: 10.1002/gcc.20330] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 4.3] [Reference Citation Analysis]
255 Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008;98:1457-66. [PMID: 18349832 DOI: 10.1038/sj.bjc.6604305] [Cited by in Crossref: 309] [Cited by in F6Publishing: 256] [Article Influence: 23.8] [Reference Citation Analysis]
256 Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer 2012;118:493-9. [PMID: 21598239 DOI: 10.1002/cncr.26191] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
257 Roessler J, Ammerpohl O, Gutwein J, Steinemann D, Schlegelberger B, Weyer V, Sariyar M, Geffers R, Arnold N, Schmutzler R. The CpG island methylator phenotype in breast cancer is associated with the lobular subtype. Epigenomics. 2015;7:187-199. [PMID: 25347269 DOI: 10.2217/epi.14.74] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
258 Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer 2020. [PMID: 32862296 DOI: 10.1007/s12282-020-01148-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
259 Bae SY, Kim SJ, Lee J, Lee ES, Kim E, Park HY, Suh YJ, Kim HK, You J, Jung SP. Clinical subtypes and prognosis of pregnancy-associated breast cancer: results from the Korean Breast Cancer Society Registry database. Breast Cancer Res Treat 2018;172:113-21. [DOI: 10.1007/s10549-018-4908-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
260 Powell CB, Littell R, Hoodfar E, Sinclair F, Pressman A. Does the Diagnosis of Breast or Ovarian Cancer Trigger Referral to Genetic Counseling? Int J Gynecol Cancer 2013;23:431-6. [DOI: 10.1097/igc.0b013e318280f2b4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
261 Bellcross C, Hermstad A, Tallo C, Stanislaw C. Validation of Version 3.0 of the Breast Cancer Genetics Referral Screening Tool (B-RST™). Genet Med 2019;21:181-4. [DOI: 10.1038/s41436-018-0020-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
262 Silverman TB, Vanegas A, Marte A, Mata J, Sin M, Ramirez JCR, Tsai WY, Crew KD, Kukafka R. Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care. BMC Health Serv Res 2018;18:633. [PMID: 30103738 DOI: 10.1186/s12913-018-3442-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
263 Edwards E, Yearwood C, Sillibourne J, Baralle D, Eccles D. Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer. Fam Cancer 2009;8:479-82. [PMID: 19629752 DOI: 10.1007/s10689-009-9270-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
264 Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, Schildkraut J, Daly MB, Isaacs C, Pichert G, Neuhausen SL, Couch FJ, van't Veer L, Eeles R, Bancroft E, Evans DG, Ganz PA, Tomlinson GE, Narod SA, Matloff E, Domchek S, Rebbeck TR. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol 2012;30:1321-8. [PMID: 22430266 DOI: 10.1200/JCO.2011.37.8133] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
265 Lynce F, Graves KD, Jandorf L, Ricker C, Castro E, Moreno L, Augusto B, Fejerman L, Vadaparampil ST. Genomic Disparities in Breast Cancer Among Latinas. Cancer Control 2016;23:359-72. [PMID: 27842325 DOI: 10.1177/107327481602300407] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
266 Michl J, Zimmer J, Tarsounas M. Interplay between Fanconi anemia and homologous recombination pathways in genome integrity. EMBO J. 2016;35:909-923. [PMID: 27037238 DOI: 10.15252/ embj.201693860] [Reference Citation Analysis]
267 Eccles BK, Copson ER, Cutress RI, Maishman T, Altman DG, Simmonds P, Gerty SM, Durcan L, Stanton L, Eccles DM, Eccles D, Simmonds P, Altman DG, Pharoah P, Warren R, Gilbert F, Jones L, Eeles R, Evans DGR, Hanby A, Thompson A, Hodgson S, Hammad H, Lakhani S. Family history and outcome of young patients with breast cancer in the UK (POSH study). British Journal of Surgery 2015;102:924-35. [DOI: 10.1002/bjs.9816] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
268 Hartikainen JM, Kataja V, Pirskanen M, Arffman A, Ristonmaa U, Vahteristo P, Ryynänen M, Heinonen S, Kosma VM, Mannermaa A. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families. Clin Genet 2007;72:311-20. [PMID: 17850627 DOI: 10.1111/j.1399-0004.2007.00866.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
269 Hosking FJ, Dobbins SE, Houlston RS. Genome-wide association studies for detecting cancer susceptibility. Br Med Bull 2011;97:27-46. [PMID: 21247937 DOI: 10.1093/bmb/ldq038] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
270 Yang V, Gouveia MJ, Santos J, Koksch B, Amorim I, Gärtner F, Vale N. Breast cancer: insights in disease and influence of drug methotrexate. RSC Med Chem 2020;11:646-64. [PMID: 33479665 DOI: 10.1039/d0md00051e] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
271 Jostins L, Barrett JC. Genetic risk prediction in complex disease. Hum Mol Genet. 2011;20:R182-R188. [PMID: 21873261 DOI: 10.1093/hmg/ddr378] [Cited by in Crossref: 122] [Cited by in F6Publishing: 100] [Article Influence: 12.2] [Reference Citation Analysis]
272 Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 2001;21:1-18. [PMID: 11443730 DOI: 10.1002/gepi.1014] [Cited by in Crossref: 192] [Cited by in F6Publishing: 156] [Article Influence: 9.6] [Reference Citation Analysis]
273 Wei Y, Wang X, Zhang Z, Xie M, Li Y, Cao H, Zhao X. Role of Polymorphisms of FAM13A, PHLDB1, and CYP24A1 in Breast Cancer Risk. CMM 2019;19:579-88. [DOI: 10.2174/1566524019666190619125109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
274 Bonadona V, Sinilnikova OM, Chopin S, Antoniou AC, Mignotte H, Mathevet P, Brémond A, Martin A, Bobin JY, Romestaing P, Raudrant D, Rudigoz RC, Léoné M, Chauvin F, Easton DF, Lenoir GM, Lasset C. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Genes Chromosomes Cancer 2005;43:404-13. [PMID: 15887246 DOI: 10.1002/gcc.20199] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
275 Thompson D, Szabo CI, Mangion J, Oldenburg RA, Odefrey F, Seal S, Barfoot R, Kroeze-Jansema K, Teare D, Rahman N, Renard H, Mann G, Hopper JL, Buys SS, Andrulis IL, Senie R, Daly MB, West D, Ostrander EA, Offit K, Peretz T, Osorio A, Benitez J, Nathanson KL, Sinilnikova OM, Olàh E, Bignon YJ, Ruiz P, Badzioch MD, Vasen HF, Futreal AP, Phelan CM, Narod SA, Lynch HT, Ponder BA, Eeles RA, Meijers-Heijboer H, Stoppa-Lyonnet D, Couch FJ, Eccles DM, Evans DG, Chang-Claude J, Lenoir G, Weber BL, Devilee P, Easton DF, Goldgar DE, Stratton MR; KConFab Consortium. Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A 2002;99:827-31. [PMID: 11792833 DOI: 10.1073/pnas.012584499] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
276 Barnes DR, Antoniou AC. Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers: Review: BRCA1/2 cancer risk modifiers. Journal of Internal Medicine 2012;271:331-43. [DOI: 10.1111/j.1365-2796.2011.02502.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
277 Hughes E, Tshiaba P, Gallagher S, Wagner S, Judkins T, Roa B, Rosenthal E, Domchek S, Garber J, Lancaster J, Weitzel J, Kurian AW, Lanchbury JS, Gutin A, Robson M. Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. JCO Precis Oncol 2020;4:PO. [PMID: 32923876 DOI: 10.1200/PO.19.00360] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 10.0] [Reference Citation Analysis]
278 Cipollini G, Tommasi S, Paradiso A, Aretini P, Bonatti F, Brunetti I, Bruno M, Lombardi G, Schittulli F, Sensi E, Tancredi M, Bevilacqua G, Caligo MA. Genetic alterations in hereditary breast cancer. Ann Oncol 2004;15 Suppl 1:I7-I13. [PMID: 15280181 DOI: 10.1093/annonc/mdh651] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
279 Antill Y, Phillips K. Screening and Diagnosis of Ovarian Cancer—High Risk. Gynecologic Cancer. Elsevier; 2004. pp. 341-54. [DOI: 10.1016/b978-0-443-07142-3.50029-4] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
280 Low YL, Wedrén S, Liu J. High-throughput genomic technology in research and clinical management of breast cancer. Evolving landscape of genetic epidemiological studies. Breast Cancer Res 2006;8:209. [PMID: 16834767 DOI: 10.1186/bcr1511] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
281 Bougie O, Weberpals JI. Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review. Int J Surg Oncol 2011;2011:374012. [PMID: 22312502 DOI: 10.1155/2011/374012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
282 Blackburn AC, Hill LZ, Roberts AL, Wang J, Aud D, Jung J, Nikolcheva T, Allard J, Peltz G, Otis CN, Cao QJ, Ricketts RS, Naber SP, Mollenhauer J, Poustka A, Malamud D, Jerry DJ. Genetic mapping in mice identifies DMBT1 as a candidate modifier of mammary tumors and breast cancer risk. Am J Pathol 2007;170:2030-41. [PMID: 17525270 DOI: 10.2353/ajpath.2007.060512] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
283 Palomba G, Pisano M, Cossu A, Budroni M, Dedola MF, Farris A, Contu A, Baldinu P, Tanda F, Palmieri G. Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening. Cancer 2005;104:1172-9. [PMID: 16047344 DOI: 10.1002/cncr.21298] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
284 Lee HB, Han W. Unique features of young age breast cancer and its management. J Breast Cancer 2014;17:301-7. [PMID: 25548576 DOI: 10.4048/jbc.2014.17.4.301] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 6.9] [Reference Citation Analysis]
285 Park YH, Lee SJ, Jung HA, Kim SM, Kim MJ, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH. Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea. Breast 2015;24:213-7. [PMID: 25728283 DOI: 10.1016/j.breast.2015.01.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
286 Whittemore AS, Gong G. Re: On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance. JNCI Journal of the National Cancer Institute 2003;95:76-7. [DOI: 10.1093/jnci/95.1.76] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
287 Narod SA. Breast cancer in young women. Nat Rev Clin Oncol 2012;9:460-70. [PMID: 22733233 DOI: 10.1038/nrclinonc.2012.102] [Cited by in Crossref: 105] [Cited by in F6Publishing: 85] [Article Influence: 11.7] [Reference Citation Analysis]
288 Vande Perre P, Toledano D, Corsini C, Escriba E, Laporte M, Bertet H, Yauy K, Toledano A, Galibert V, Baudry K, Clotet L, Million E, Picot MC, Geneviève D, Pujol P. Role of the general practitioner in the care of BRCA1 and BRCA2 mutation carriers: General practitioner and patient perspectives. Mol Genet Genomic Med 2018;6:957-65. [PMID: 30308700 DOI: 10.1002/mgg3.464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
289 Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Górski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H, Spurdle AB, Chen X, Waddell N, Cloonan N, Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G; Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO)., Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE)., German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC)., Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab)., Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007;81:1186-200. [PMID: 17999359 DOI: 10.1086/522611] [Cited by in Crossref: 182] [Cited by in F6Publishing: 170] [Article Influence: 13.0] [Reference Citation Analysis]
290 Coyne ZL, Hennessy M, Duke D, Hill A, Grogan L, Breathnach O, Hennessy B, Morris PG. Patient demographics and management challenges in an Irish symptomatic breast cancer unit. Ir J Med Sci 2020;189:1237-41. [PMID: 32436172 DOI: 10.1007/s11845-020-02245-z] [Reference Citation Analysis]
291 Arslan Ateş E, Türkyilmaz A, Yıldırım Ö, Alavanda C, Polat H, Demir Ş, Çebi AH, Geçkinli BB, Güney Aİ, Ata P, Arman A. Secondary findings in 622 Turkish clinical exome sequencing data. J Hum Genet 2021. [PMID: 34050257 DOI: 10.1038/s10038-021-00936-8] [Reference Citation Analysis]
292 Rich TA, Woodson AH, Litton J, Arun B. Hereditary breast cancer syndromes and genetic testing: Breast Cancer Syndromes and Genetic Testing. J Surg Oncol 2015;111:66-80. [DOI: 10.1002/jso.23791] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
293 Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med 2017;23:517-25. [PMID: 28288110 DOI: 10.1038/nm.4292] [Cited by in Crossref: 365] [Cited by in F6Publishing: 276] [Article Influence: 91.3] [Reference Citation Analysis]
294 Jobsen JJ, van der Palen J, Brinkhuis M, Ong F, Struikmans H. Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer. Acta Oncol 2016;55:449-54. [PMID: 26399280 DOI: 10.3109/0284186X.2015.1074281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
295 Judkins T, Rosenthal E, Arnell C, Burbidge LA, Geary W, Barrus T, Schoenberger J, Trost J, Wenstrup RJ, Roa BB. Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer 2012;118:5210-6. [PMID: 22544547 DOI: 10.1002/cncr.27556] [Cited by in Crossref: 91] [Cited by in F6Publishing: 69] [Article Influence: 10.1] [Reference Citation Analysis]
296 Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-6. [PMID: 11984562 DOI: 10.1038/ng853] [Cited by in Crossref: 542] [Cited by in F6Publishing: 456] [Article Influence: 28.5] [Reference Citation Analysis]
297 Easton DF. Familial risks of breast cancer. Breast Cancer Res 2002;4:179-81. [PMID: 12223120 DOI: 10.1186/bcr448] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 2.7] [Reference Citation Analysis]
298 Rubinstein WS. Hereditary breast cancer in Jews. Familial Cancer 2004;3:249-57. [DOI: 10.1007/s10689-004-9550-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
299 Bellcross CA, Lemke AA, Pape LS, Tess AL, Meisner LT. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med 2009;11:783-9. [DOI: 10.1097/gim.0b013e3181b9b04a] [Cited by in Crossref: 66] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
300 Suthers GK. CANCER RISKS FOR AUSTRALIAN WOMEN WITH A BRCA1 OR A BRCA2 MUTATION. ANZ J Surg 2007;77:314-9. [DOI: 10.1111/j.1445-2197.2007.04050.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
301 Sizemore ST, Mohammad R, Sizemore GM, Nowsheen S, Yu H, Ostrowski MC, Chakravarti A, Xia F. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent. Mol Cancer Res 2018;16:1092-102. [PMID: 29592899 DOI: 10.1158/1541-7786.MCR-18-0106] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
302 Yao L, Sun J, Zhang J, He Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. Breast Cancer Res Treat 2016;156:441-5. [DOI: 10.1007/s10549-016-3766-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
303 Antoniou AC, Durocher F, Smith P, Simard J, Easton DF; INHERIT BRCAs program members. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 2006;8:R3. [PMID: 16417652 DOI: 10.1186/bcr1365] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
304 Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007;25:2921-2927. [PMID: 17617523 DOI: 10.1200/jco.2007.11.3449] [Cited by in Crossref: 104] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
305 Lalloo F, Evans DG. Familial breast cancer. Clin Genet. 2012;82:105-114. [PMID: 22356477 DOI: 10.1111/j.1399-0004.2012.01859.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 80] [Article Influence: 12.1] [Reference Citation Analysis]
306 Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26:1331-1337. [PMID: 18268356 DOI: 10.1200/jco.2007.13.9626] [Cited by in Crossref: 393] [Cited by in F6Publishing: 137] [Article Influence: 30.2] [Reference Citation Analysis]
307 Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32:783-790. [PMID: 24516018 DOI: 10.1200/jco.2013.49.3726] [Cited by in Crossref: 258] [Cited by in F6Publishing: 135] [Article Influence: 36.9] [Reference Citation Analysis]
308 Palma G, Frasci G, Chirico A, Esposito E, Siani C, Saturnino C, Arra C, Ciliberto G, Giordano A, D'Aiuto M. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget 2015;6:26560-74. [PMID: 26387133 DOI: 10.18632/oncotarget.5306] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 17.6] [Reference Citation Analysis]
309 Katapodi MC, Viassolo V, Caiata-Zufferey M, Nikolaidis C, Bührer-Landolt R, Buerki N, Graffeo R, Horváth HC, Kurzeder C, Rabaglio M, Scharfe M, Urech C, Erlanger TE, Probst-Hensch N, Heinimann K, Heinzelmann-Schwarz V, Pagani O, Chappuis PO. Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol. JMIR Res Protoc 2017;6:e184. [PMID: 28931501 DOI: 10.2196/resprot.8138] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
310 Liang Y, Yang X, Li H, Zhu A, Guo Z, Li M. Prevalence and Spectrum of BRCA1/2 Germline Mutations in Women with Breast Cancer in China Based on Next-Generation Sequencing. Med Sci Monit 2018;24:2465-75. [PMID: 29681614 DOI: 10.12659/msm.905812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
311 Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S, Gulcher JR, Bjornsson J, Kong A, Thorsteinsdottir U, Stefansson K. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 2004;1:e65. [PMID: 15630470 DOI: 10.1371/journal.pmed.0010065] [Cited by in Crossref: 195] [Cited by in F6Publishing: 180] [Article Influence: 11.5] [Reference Citation Analysis]
312 Loman N, Bladström A, Johannsson O, Borg A, Olsson H. Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res 2003;5:R175-86. [PMID: 14580253 DOI: 10.1186/bcr632] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
313 Glidden DV, Liang K, Chiu Y, Pulver AE. Multipoint affected sibpair linkage methods for localizing susceptibility genes of complex diseases. Genet Epidemiol 2003;24:107-17. [DOI: 10.1002/gepi.10215] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
314 Karellas A. Mammographic pattern analysis: an emerging risk assessment tool. Acad Radiol 2007;14:511-2. [PMID: 17434063 DOI: 10.1016/j.acra.2007.03.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
315 Schaapveld M, Visser O, Louwman MJ, de Vries EG, Willemse PH, Otter R, van der Graaf WT, Coebergh JW, van Leeuwen FE. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol. 2008;26:1239-1246. [PMID: 18323547 DOI: 10.1200/jco.2007.11.9081] [Cited by in Crossref: 124] [Cited by in F6Publishing: 58] [Article Influence: 9.5] [Reference Citation Analysis]
316 Al Bakir M, Gabra H. The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future. British Medical Bulletin 2014;112:57-69. [DOI: 10.1093/bmb/ldu034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
317 Peleg Hasson S, Menes T, Sonnenblick A. Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes. Pharmgenomics Pers Med 2020;13:227-38. [PMID: 32801835 DOI: 10.2147/PGPM.S233485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
318 Haanpää M, Reiman M, Nikkilä J, Erkko H, Pylkäs K, Winqvist R. Mutation analysis of the AATF gene in breast cancer families. BMC Cancer 2009;9:457. [PMID: 20025740 DOI: 10.1186/1471-2407-9-457] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
319 Henningson M, Bågeman E, Sandberg T, Borg Å, Olsson H, Jernström H. Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families. Familial Cancer 2007;6:445-52. [DOI: 10.1007/s10689-007-9141-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
320 Maxwell KN, Domchek SM, Nathanson KL, Robson ME. Population Frequency of Germline BRCA1/2 Mutations. J Clin Oncol 2016;34:4183-5. [PMID: 27551127 DOI: 10.1200/JCO.2016.67.0554] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 10.6] [Reference Citation Analysis]
321 Sud A, Kinnersley B, Houlston RS. Genome-wide association studies of cancer: current insights and future perspectives. Nat Rev Cancer 2017;17:692-704. [PMID: 29026206 DOI: 10.1038/nrc.2017.82] [Cited by in Crossref: 151] [Cited by in F6Publishing: 101] [Article Influence: 37.8] [Reference Citation Analysis]
322 Beck AC, Yuan H, Liao J, Imperiale P, Shipley K, Erdahl LM, Sugg SL, Weigel RJ, Lizarraga IM. Rate of BRCA mutation in patients tested under NCCN genetic testing criteria. Am J Surg 2020;219:145-9. [PMID: 31255259 DOI: 10.1016/j.amjsurg.2019.06.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
323 Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age of onset in familial cancer. Ann Oncol 2008;19:2084-8. [PMID: 18653701 DOI: 10.1093/annonc/mdn527] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
324 Zhou J, Nagarkatti PS, Zhong Y, Zhang J, Nagarkatti M. Implications of single nucleotide polymorphisms in CD44 exon 2 for risk of breast cancer. Eur J Cancer Prev 2011;20:396-402. [PMID: 21804359 DOI: 10.1097/CEJ.0b013e3283463943] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
325 Torrezan GT, de Almeida FGDSR, Figueiredo MCP, Barros BDF, de Paula CAA, Valieris R, de Souza JES, Ramalho RF, da Silva FCC, Ferreira EN, de Nóbrega AF, Felicio PS, Achatz MI, de Souza SJ, Palmero EI, Carraro DM. Complex Landscape of Germline Variants in Brazilian Patients With Hereditary and Early Onset Breast Cancer. Front Genet 2018;9:161. [PMID: 29868112 DOI: 10.3389/fgene.2018.00161] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
326 Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang W. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics 2012;13:1523-35. [PMID: 23057551 DOI: 10.2217/pgs.12.137] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
327 Kwong A, Ng EK, Wong CL, Law FB, Au T, Wong HN, Kurian AW, West DW, Ford JM, Ma ES. Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. PLoS One 2012;7:e43994. [PMID: 22970155 DOI: 10.1371/journal.pone.0043994] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 6.3] [Reference Citation Analysis]
328 Bove B, Dunbrack R, Godwin A. BRCA-1, BRCA-2 and Hereditary Breast Cancer. In: Pasqualini J, editor. Breast Cancer. CRC Press; 2002. pp. 555-624. [DOI: 10.1201/b14039-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
329 Schoemaker MJ, Jones ME, Higgins CD, Wright AF, Swerdlow AJ; UK Clinical Cytogenetics Group. Mortality and cancer incidence in carriers of constitutional t(11;22)(q23;q11) translocations: A prospective study. Int J Cancer 2019;145:1493-8. [PMID: 30496607 DOI: 10.1002/ijc.32031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
330 Armstrong J, Toscano M, Kotchko N, Friedman S, Schwartz MD, Virgo KS, Lynch K, Andrews JE, Aguado Loi CX, Bauer JE, Casares C, Teten RT, Kondoff MR, Molina AD, Abdollahian M, Brand L, Walker GS, Sutphen R. American BRCA Outcomes and Utilization of Testing (ABOUT) study: a pragmatic research model that incorporates personalized medicine/patient-centered outcomes in a real world setting. J Genet Couns 2015;24:18-28. [PMID: 25209347 DOI: 10.1007/s10897-014-9750-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
331 Woodward ER, van Veen EM, Forde C, Harkness EF, Byers HJ, Ellingford JM, Burghel GJ, Schlech H, Bowers NL, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ, Gareth Evans D. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. Genet Med 2021. [PMID: 34113003 DOI: 10.1038/s41436-021-01234-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
332 Gravitt PE. The known unknowns of HPV natural history. J Clin Invest 2011;121:4593-9. [PMID: 22133884 DOI: 10.1172/JCI57149] [Cited by in Crossref: 212] [Cited by in F6Publishing: 90] [Article Influence: 21.2] [Reference Citation Analysis]
333 Scott CL, Jenkins MA, Southey MC, Davis TA, Leary JA, Easton DF, Phillips KA, Hopper JL. Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. Hum Genet 2003;112:542-51. [PMID: 12601471 DOI: 10.1007/s00439-003-0908-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
334 Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98:1694-1706. [PMID: 17148771 DOI: 10.1093/jnci/djj465] [Cited by in Crossref: 469] [Cited by in F6Publishing: 385] [Article Influence: 33.5] [Reference Citation Analysis]
335 Hasmad HN, Lai KN, Wen WX, Park DJ, Nguyen-Dumont T, Kang PCE, Thirthagiri E, Ma'som M, Lim BK, Southey M, Woo YL, Teo SH. Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients. Gynecol Oncol. 2016;141:318-322. [PMID: 26541979 DOI: 10.1016/j.ygyno.2015.11.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
336 CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet. 2004;74:1175-1182. [PMID: 15122511 DOI: 10.1086/421251] [Cited by in Crossref: 330] [Cited by in F6Publishing: 283] [Article Influence: 19.4] [Reference Citation Analysis]
337 Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight JA, Goodwin PJ, Andrulis IL, O'Malley FP. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer 2002;95:2068-75. [PMID: 12412159 DOI: 10.1002/cncr.10949] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
338 Guo F, Hirth JM, Lin YL, Richardson G, Levine L, Berenson AB, Kuo YF. Use of BRCA Mutation Test in the U.S., 2004-2014. Am J Prev Med 2017;52:702-9. [PMID: 28342662 DOI: 10.1016/j.amepre.2017.01.027] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 9.5] [Reference Citation Analysis]
339 Batalini F, Peacock EG, Stobie L, Robertson A, Garber J, Weitzel JN, Tung NM. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Res 2019;21:107. [PMID: 31533767 DOI: 10.1186/s13058-019-1193-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
340 Meaney-Delman D, Bellcross CA. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists. Obstet Gynecol Clin North Am. 2013;40:475-512. [PMID: 24021253 DOI: 10.1016/j.ogc.2013.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
341 Larsen MJ, Kruse TA, Tan Q, Lænkholm AV, Bak M, Lykkesfeldt AE, Sørensen KP, Hansen TV, Ejlertsen B, Gerdes AM, Thomassen M. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. PLoS One 2013;8:e64268. [PMID: 23704984 DOI: 10.1371/journal.pone.0064268] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
342 Meiser B, Tucker K, Friedlander M, Barlow-Stewart K, Lobb E, Saunders C, Mitchell G. Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Res 2008;10:216. [PMID: 19090970 DOI: 10.1186/bcr2194] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
343 Domchek SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer 2013;119:1344-8. [PMID: 23165893 DOI: 10.1002/cncr.27842] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
344 Graña B, Fachal L, Darder E, Balmaña J, Ramón Y Cajal T, Blanco I, Torres A, Lázaro C, Diez O, Alonso C, Santamariña M, Velasco A, Teulé A, Lasa A, Blanco A, Izquierdo A, Borràs J, Gutiérrez-Enríquez S, Vega A, Brunet J. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry. Breast Cancer Res Treat 2011;128:573-9. [PMID: 21445571 DOI: 10.1007/s10549-011-1462-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
345 Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 2008;40:17-22. [PMID: 18163131 DOI: 10.1038/ng.2007.53] [Cited by in Crossref: 340] [Cited by in F6Publishing: 285] [Article Influence: 26.2] [Reference Citation Analysis]
346 Solyom S, Patterson-Fortin J, Pylkäs K, Greenberg RA, Winqvist R. Mutation screening of the MERIT40 gene encoding a novel BRCA1 and RAP80 interacting protein in breast cancer families. Breast Cancer Res Treat 2010;120:165-8. [PMID: 19572197 DOI: 10.1007/s10549-009-0453-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
347 Choi DH, Lee MH, Bale AE, Carter D, Haffty BG. Incidence of BRCA1 and BRCA2 Mutations in Young Korean Breast Cancer Patients. JCO 2004;22:1638-45. [DOI: 10.1200/jco.2004.04.179] [Cited by in Crossref: 84] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
348 Møller P, Heimdal K, Apold J, Fredriksen A, Borg A, Hovig E, Hagen A, Hagen B, Pedersen JC, Maehle L; Norwegian Inherited Breast Cancer Group., Norwegian Inherited Ovarian Cancer Group. Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer 2001;37:2428-34. [PMID: 11720839 DOI: 10.1016/s0959-8049(01)00299-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
349 Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PDP, Easton DF, Day NE, Ponder BAJ. Polymorphisms Associated With Circulating Sex Hormone Levels in Postmenopausal Women. JNCI Journal of the National Cancer Institute 2004;96:936-45. [DOI: 10.1093/jnci/djh167] [Cited by in Crossref: 238] [Cited by in F6Publishing: 223] [Article Influence: 14.0] [Reference Citation Analysis]
350 Lalloo F, Varley J, Ellis D, Moran A, O'dair L, Pharoah P, Evans DGR. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. The Lancet 2003;361:1101-2. [DOI: 10.1016/s0140-6736(03)12856-5] [Cited by in Crossref: 133] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
351 Ross LF. Should Children and Adolescents Undergo Genetic Testing? Pediatr Ann 2004;33:762-9. [DOI: 10.3928/0090-4481-20041101-11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
352 Tilanus-linthorst MM, Lingsma HF, Evans DG, Thompson D, Kaas R, Manders P, van Asperen CJ, Adank M, Hooning MJ, Kwan Lim GE, Eeles R, Oosterwijk JC, Leach MO, Steyerberg EW. Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk: Optimal age to start breast cancer prevention. Int J Cancer 2013;133:156-63. [DOI: 10.1002/ijc.28014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]